

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	171	cysk or cysteine synthase\$1	US-PGPUB; USPAT	ADJ	OFF	2006/03/10 13:07
(L2)	127	1 same (gene\$1 or sequence\$1 or nucleic or polynucleotide\$)	US-PGPUB; USPAT	ADJ	OFF	2006/03/10 16:03
L3	118438	(serine or ser) same (coexpress\$ or rich or high or level\$1 or yield\$1 or optimiz\$)	US-PGPUB; USPAT	ADJ	OFF	2006/03/10 16:05
L4	63	1 and 3	US-PGPUB; USPAT	ADJ	OFF	2006/03/10 16:06
(L5)	18	4 not 2	US-PGPUB; USPAT	ADJ	OFF	2006/03/10 16:15
L6	6745	(amino acid\$1) near5 protein\$1 near5 (production\$ or express\$ or optimiz\$)	US-PGPUB; USPAT	ADJ	OFF	2006/03/10 16:19
L7	949	6 same coli	US-PGPUB; USPAT	ADJ	OFF	2006/03/10 16:18
L9	206	(amino acid\$1) near5 (composition\$ or profile\$) near5 protein\$1 near5 (production\$ or express\$ or optimiz\$)	US-PGPUB; USPAT	ADJ	OFF	2006/03/10 16:24
(L10)	5	9 same coli	US-PGPUB; USPAT	ADJ	OFF	2006/03/10 16:21
(L11)	12	(amino acid\$1) near5 (composition\$ or profile\$) near5 (heterologous or foreign) near3 protein\$1 near5 (production\$ or express\$ or optimiz\$)	US-PGPUB; USPAT	ADJ	OFF	2006/03/10 16:27
(L12)	1	1 same coexpress\$	US-PGPUB; USPAT	ADJ	OFF	2006/03/10 16:28
(L13)	77	1 same (serine or ser)	US-PGPUB; USPAT	ADJ	OFF	2006/03/10 16:29
(L14)	20	13 not 2	US-PGPUB; USPAT	ADJ	OFF	2006/03/10 16:29

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:09:38 ON 10 MAR 2006

=> fil .bec

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILES 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS,
ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 17:09:59 ON 10 MAR 2006
ALL COPYRIGHTS AND RESTRICTIONS APPLY. SEE HELP USAGETERMS FOR DETAILS.

11 FILES IN THE FILE LIST

=> s cysk or cysteine synthase#

FILE 'MEDLINE'

77 CYSK

64899 CYSTEINE

92418 SYNTHASE#

228 CYSTEINE SYNTHASE#

(CYSTEINE(W)SYNTHASE#)

L1 265 CYSK OR CYSTEINE SYNTHASE#

FILE 'SCISEARCH'

52 CYSK

47434 CYSTEINE

107943 SYNTHASE#

200 CYSTEINE SYNTHASE#

(CYSTEINE(W)SYNTHASE#)

L2 233 CYSK OR CYSTEINE SYNTHASE#

FILE 'LIFESCI'

48 CYSK

18083 "CYSTEINE"

23974 SYNTHASE#

88 CYSTEINE SYNTHASE#

("CYSTEINE"(W)SYNTHASE#)

L3 120 CYSK OR CYSTEINE SYNTHASE#

FILE 'BIOTECHDS'

51 CYSK

4197 CYSTEINE

6065 SYNTHASE#

59 CYSTEINE SYNTHASE#

(CYSTEINE(W)SYNTHASE#)

L4 79 CYSK OR CYSTEINE SYNTHASE#

FILE 'BIOSIS'

76 CYSK

59077 CYSTEINE

99656 SYNTHASE#

217 CYSTEINE SYNTHASE#

(CYSTEINE(W)SYNTHASE#)

L5 273 CYSK OR CYSTEINE SYNTHASE#

FILE 'EMBASE'

58 CYSK

49436 "CYSTEINE"

90470 SYNTHASE#

194 CYSTEINE SYNTHASE#

("CYSTEINE"(W)SYNTHASE#)

L6 223 CYSK OR CYSTEINE SYNTHASE#

FILE 'HCAPLUS'

175 CYSK
100024 CYSTEINE
94834 SYNTHASE#
359 CYSTEINE SYNTHASE#
(CYSTEINE(W) SYNTHASE#)
L7 451 CYSK OR CYSTEINE SYNTHASE#

FILE 'NTIS'
0 CYSK
490 CYSTEINE
232 SYNTHASE#
0 CYSTEINE SYNTHASE#
(CYSTEINE(W) SYNTHASE#)
L8 0 CYSK OR CYSTEINE SYNTHASE#

FILE 'ESBIOBASE'
41 CYSK
23741 CYSTEINE
44267 SYNTHASE#
96 CYSTEINE SYNTHASE#
(CYSTEINE(W) SYNTHASE#)
L9 122 CYSK OR CYSTEINE SYNTHASE#

FILE 'BIOTECHNO'
43 CYSK
22339 CYSTEINE
29457 SYNTHASE#
130 CYSTEINE SYNTHASE#
(CYSTEINE(W) SYNTHASE#)
L10 151 CYSK OR CYSTEINE SYNTHASE#

FILE 'WPIDS'
44 CYSK
8434 CYSTEINE
4985 SYNTHASE#
43 CYSTEINE SYNTHASE#
(CYSTEINE(W) SYNTHASE#)
L11 58 CYSK OR CYSTEINE SYNTHASE#

TOTAL FOR ALL FILES
L12 1975 CYSK OR CYSTEINE SYNTHASE#

=> s (serine or ser) (15a) (rich or high or level# or yield# or optimiz?)

FILE 'MEDLINE'
89374 SERINE
21253 SER
82402 RICH
1384133 HIGH
1482581 LEVEL#
120679 YIELD#
62852 OPTIMIZ?
L13 5214 (SERINE OR SER) (15A) (RICH OR HIGH OR LEVEL# OR YIELD# OR OPTIMIZ
?)

FILE 'SCISEARCH'
51760 SERINE
21683 SER
151346 RICH
2077769 HIGH
1544858 LEVEL#
395337 YIELD#
231907 OPTIMIZ?
L14 4738 (SERINE OR SER) (15A) (RICH OR HIGH OR LEVEL# OR YIELD# OR OPTIMIZ
?)

FILE 'LIFESCI'
 21346 SERINE
 10414 SER
 34806 RICH
 371067 HIGH
 429126 LEVEL#
 54802 YIELD#
 16670 OPTIMIZ?
 L15 2904 (SERINE OR SER) (15A) (RICH OR HIGH OR LEVEL# OR YIELD# OR OPTIMIZ
 ?)

FILE 'BIOTECHDS'
 4795 SERINE
 4602 SER
 4493 RICH
 74156 HIGH
 51021 LEVEL#
 39614 YIELD#
 18716 OPTIMIZ?
 L16 601 (SERINE OR SER) (15A) (RICH OR HIGH OR LEVEL# OR YIELD# OR OPTIMIZ
 ?)

FILE 'BIOSIS'
 68149 SERINE
 22012 SER
 105895 RICH
 1493999 HIGH
 1613796 LEVEL#
 298893 YIELD#
 67102 OPTIMIZ?
 L17 5953 (SERINE OR SER) (15A) (RICH OR HIGH OR LEVEL# OR YIELD# OR OPTIMIZ
 ?)

FILE 'EMBASE'
 56820 SERINE
 18916 SER
 74243 RICH
 1329455 HIGH
 1698265 LEVEL#
 134210 YIELD#
 62502 OPTIMIZ?
 L18 4606 (SERINE OR SER) (15A) (RICH OR HIGH OR LEVEL# OR YIELD# OR OPTIMIZ
 ?)

FILE 'HCAPLUS'
 105605 SERINE
 34615 SER
 275173 RICH
 3744857 HIGH
 2249255 LEVEL#
 1150857 YIELD#
 289102 OPTIMIZ?
 L19 9041 (SERINE OR SER) (15A) (RICH OR HIGH OR LEVEL# OR YIELD# OR OPTIMIZ
 ?)

FILE 'NTIS'
 523 SERINE
 403 SER
 9236 RICH
 328134 HIGH
 228017 LEVEL#
 55396 YIELD#
 59744 OPTIMIZ?
 L20 76 (SERINE OR SER) (15A) (RICH OR HIGH OR LEVEL# OR YIELD# OR OPTIMIZ
 ?)

FILE 'ESBIOBASE'
26942 SERINE
12423 SER
45135 RICH
510678 HIGH
573275 LEVEL#
74897 YIELD#
30661 OPTIMIZ?
L21 3577 (SERINE OR SER) (15A) (RICH OR HIGH OR LEVEL# OR YIELD# OR OPTIMIZ
?)

FILE 'BIOTECHNO'
28989 SERINE
11924 SER
29372 RICH
299126 HIGH
367944 LEVEL#
41645 YIELD#
16086 OPTIMIZ?
L22 3241 (SERINE OR SER) (15A) (RICH OR HIGH OR LEVEL# OR YIELD# OR OPTIMIZ
?)

FILE 'WPIDS'
8297 SERINE
9747 SER
33876 RICH
2046959 HIGH
610630 LEVEL#
249912 YIELD#
41189 OPTIMIZ?
L23 492 (SERINE OR SER) (15A) (RICH OR HIGH OR LEVEL# OR YIELD# OR OPTIMIZ
?)

TOTAL FOR ALL FILES
L24 40443 (SERINE OR SER) (15A) (RICH OR HIGH OR LEVEL# OR YIELD# OR OPTIMIZ
?)

=> s l12 and l24
FILE 'MEDLINE'
L25 12 L1 AND L13

FILE 'SCISEARCH'
L26 9 L2 AND L14

FILE 'LIFESCI'
L27 5 L3 AND L15

FILE 'BIOTECHDS'
L28 2 L4 AND L16

FILE 'BIOSIS'
L29 9 L5 AND L17

FILE 'EMBASE'
L30 5 L6 AND L18

FILE 'HCAPLUS'
L31 11 L7 AND L19

FILE 'NTIS'
L32 0 L8 AND L20

FILE 'ESBIOBASE'
L33 4 L9 AND L21

FILE 'BIOTECHNO'
L34 8 L10 AND L22

FILE 'WPIDS'
L35 1 L11 AND L23

TOTAL FOR ALL FILES
L36 66 L12 AND L24

=> s l12 and coexpress?
FILE 'MEDLINE'
13548 COEXPRESS?
L37 2 L1 AND COEXPRESS?

FILE 'SCISEARCH'
13934 COEXPRESS?
L38 2 L2 AND COEXPRESS?

FILE 'LIFESCI'
6199 COEXPRESS?
L39 2 L3 AND COEXPRESS?

FILE 'BIOTECHDS'
660 COEXPRESS?
L40 1 L4 AND COEXPRESS?

FILE 'BIOSIS'
13729 COEXPRESS?
L41 2 L5 AND COEXPRESS?

FILE 'EMBASE'
12791 COEXPRESS?
L42 1 L6 AND COEXPRESS?

FILE 'HCAPLUS'
12757 COEXPRESS?
L43 2 L7 AND COEXPRESS?

FILE 'NTIS'
33 COEXPRESS?
L44 0 L8 AND COEXPRESS?

FILE 'ESBIOBASE'
9809 COEXPRESS?
L45 1 L9 AND COEXPRESS?

FILE 'BIOTECHNO'
7587 COEXPRESS?
L46 1 L10 AND COEXPRESS?

FILE 'WPIDS'
140 COEXPRESS?
L47 0 L11 AND COEXPRESS?

TOTAL FOR ALL FILES
L48 14 L12 AND COEXPRESS?

=> s (amino acid or ser or serine) (15a) (composition# or profil?)
FILE 'MEDLINE'
612125 AMINO
1387745 ACID
459057 AMINO ACID
(AMINO (W) ACID)
21253 SER

89374 SERINE
162979 COMPOSITION#
236020 PROFIL?
L49 13569 (AMINO ACID OR SER OR SERINE) (15A) (COMPOSITION# OR PROFIL?)

FILE 'SCISEARCH'

385550 AMINO
1114189 ACID
204369 AMINO ACID
(AMINO (W) ACID)
21683 SER
51760 SERINE
404372 COMPOSITION#
365251 PROFIL?
L50 9303 (AMINO ACID OR SER OR SERINE) (15A) (COMPOSITION# OR PROFIL?)

FILE 'LIFESCI'

166826 "AMINO"
297172 "ACID"
115086 AMINO ACID
("AMINO" (W) "ACID")
10414 SER
21346 SERINE
97038 COMPOSITION#
52629 PROFIL?
L51 6007 (AMINO ACID OR SER OR SERINE) (15A) (COMPOSITION# OR PROFIL?)

FILE 'BIOTECHDS'

66035 AMINO
135710 ACID
47319 AMINO ACID
(AMINO (W) ACID)
4602 SER
4795 SERINE
40424 COMPOSITION#
10048 PROFIL?
L52 2448 (AMINO ACID OR SER OR SERINE) (15A) (COMPOSITION# OR PROFIL?)

FILE 'BIOSIS'

521001 AMINO
1241250 ACID
303253 AMINO ACID
(AMINO (W) ACID)
22012 SER
68149 SERINE
321074 COMPOSITION#
229122 PROFIL?
L53 21821 (AMINO ACID OR SER OR SERINE) (15A) (COMPOSITION# OR PROFIL?)

FILE 'EMBASE'

421666 "AMINO"
1369373 "ACID"
285316 AMINO ACID
("AMINO" (W) "ACID")
18916 SER
56820 SERINE
146585 COMPOSITION#
199373 PROFIL?
L54 13021 (AMINO ACID OR SER OR SERINE) (15A) (COMPOSITION# OR PROFIL?)

FILE 'HCAPLUS'

1060945 AMINO
4112384 ACID
526592 AMINO ACID
(AMINO (W) ACID)

34615 SER
 105605 SERINE
 940605 COMPOSITION#
 1384879 COMPN
 1938054 COMPOSITION#
 (COMPOSITION# OR COMPN)
 422290 PROFIL?
 L55 37840 (AMINO ACID OR SER OR SERINE) (15A) (COMPOSITION# OR PROFIL?)

FILE 'NTIS'

6961 AMINO
 43883 ACID
 2458 AMINO ACID
 (AMINO (W) ACID)
 403 SER
 523 SERINE
 69557 COMPOSITION#
 57548 PROFIL?
 L56 223 (AMINO ACID OR SER OR SERINE) (15A) (COMPOSITION# OR PROFIL?)

FILE 'ESBIOBASE'

177493 AMINO
 336489 ACID
 98921 AMINO ACID
 (AMINO (W) ACID)
 12423 SER
 26942 SERINE
 82506 COMPOSITION#
 91500 PROFIL?
 L57 3439 (AMINO ACID OR SER OR SERINE) (15A) (COMPOSITION# OR PROFIL?)

FILE 'BIOTECHNO'

204625 AMINO
 349810 ACID
 154660 AMINO ACID
 (AMINO (W) ACID)
 11924 SER
 28989 SERINE
 38895 COMPOSITION#
 42958 PROFIL?
 L58 6366 (AMINO ACID OR SER OR SERINE) (15A) (COMPOSITION# OR PROFIL?)

FILE 'WPIDS'

244392 AMINO
 937777 ACID
 68710 AMINO ACID
 (AMINO (W) ACID)
 9747 SER
 8297 SERINE
 707136 COMPOSITION#
 8956 COMPN
 388438 COMPSN
 111886 COMPSNS
 879081 COMPOSITION#
 (COMPOSITION# OR COMPN OR COMPSN OR COMPSNS)
 194379 PROFIL?
 L59 4757 (AMINO ACID OR SER OR SERINE) (15A) (COMPOSITION# OR PROFIL?)

TOTAL FOR ALL FILES

L60 118794 (AMINO ACID OR SER OR SERINE) (15A) (COMPOSITION# OR PROFIL?)

=> s 112 and 160

FILE 'MEDLINE'

L61 7 L1 AND L49

FILE 'SCISEARCH'
L62 8 L2 AND L50

FILE 'LIFESCI'
L63 3 L3 AND L51

FILE 'BIOTECHDS'
L64 1 L4 AND L52

FILE 'BIOSIS'
L65 18 L5 AND L53

FILE 'EMBASE'
L66 6 L6 AND L54

FILE 'HCAPLUS'
L67 16 L7 AND L55

FILE 'NTIS'
L68 0 L8 AND L56

FILE 'ESBIOBASE'
L69 3 L9 AND L57

FILE 'BIOTECHNO'
L70 4 L10 AND L58

FILE 'WPIDS'
L71 0 L11 AND L59

TOTAL FOR ALL FILES
L72 66 L12 AND L60

=> s (heterologous or foreign or recombinant) (5a) (protein#) (10a) (produc? or
express? or optimiz?)

FILE 'MEDLINE'
47718 HETEROLOGOUS
59253 FOREIGN
260330 RECOMBINANT
1917452 PROTEIN#
1292191 PRODUC?
987095 EXPRESS?
62852 OPTIMIZ?
L73 9273 (HETEROLOGOUS OR FOREIGN OR RECOMBINANT) (5A) (PROTEIN#) (10A) (PROD
UC? OR EXPRESS? OR OPTIMIZ?)

FILE 'SCISEARCH'
22183 HETEROLOGOUS
30720 FOREIGN
151971 RECOMBINANT
1506451 PROTEIN#
1820406 PRODUC?
1264806 EXPRESS?
231907 OPTIMIZ?
L74 9497 (HETEROLOGOUS OR FOREIGN OR RECOMBINANT) (5A) (PROTEIN#) (10A) (PROD
UC? OR EXPRESS? OR OPTIMIZ?)

FILE 'LIFESCI'
14826 HETEROLOGOUS
8447 FOREIGN
66783 RECOMBINANT
557087 PROTEIN#
514871 PRODUC?
391866 EXPRESS?

16670 OPTIMIZ?
L75 7060 (HETEROLOGOUS OR FOREIGN OR RECOMBINANT) (5A) (PROTEIN#) (10A) (PROD
UC? OR EXPRESS? OR OPTIMIZ?)

FILE 'BIOTECHDS'

10884 HETEROLOGOUS
6430 FOREIGN
97090 RECOMBINANT
151602 PROTEIN#
222303 PRODUC?
140581 EXPRESS?
18716 OPTIMIZ?
L76 28528 (HETEROLOGOUS OR FOREIGN OR RECOMBINANT) (5A) (PROTEIN#) (10A) (PROD
UC? OR EXPRESS? OR OPTIMIZ?)

FILE 'BIOSIS'

29246 HETEROLOGOUS
27340 FOREIGN
190479 RECOMBINANT
1776662 PROTEIN#
1712468 PRODUC?
1177112 EXPRESS?
67102 OPTIMIZ?
L77 11496 (HETEROLOGOUS OR FOREIGN OR RECOMBINANT) (5A) (PROTEIN#) (10A) (PROD
UC? OR EXPRESS? OR OPTIMIZ?)

FILE 'EMBASE'

22283 HETEROLOGOUS
32257 FOREIGN
168217 RECOMBINANT
1528079 PROTEIN#
1234355 PRODUC?
900431 EXPRESS?
62502 OPTIMIZ?
L78 7669 (HETEROLOGOUS OR FOREIGN OR RECOMBINANT) (5A) (PROTEIN#) (10A) (PROD
UC? OR EXPRESS? OR OPTIMIZ?)

FILE 'HCAPLUS'

31811 HETEROLOGOUS
44935 FOREIGN
181959 RECOMBINANT
2145009 PROTEIN#
4210196 PRODUC?
925167 PRODN
4658156 PRODUC?
(PRODUC? OR PRODN)
1198161 EXPRESS?
289102 OPTIMIZ?
L79 21347 (HETEROLOGOUS OR FOREIGN OR RECOMBINANT) (5A) (PROTEIN#) (10A) (PROD
UC? OR EXPRESS? OR OPTIMIZ?)

FILE 'NTIS'

303 HETEROLOGOUS
384442 FOREIGN
1594 RECOMBINANT
18611 PROTEIN#
370125 PRODUC?
39074 EXPRESS?
59744 OPTIMIZ?
L80 139 (HETEROLOGOUS OR FOREIGN OR RECOMBINANT) (5A) (PROTEIN#) (10A) (PROD
UC? OR EXPRESS? OR OPTIMIZ?)

FILE 'ESBIOBASE'

12834 HETEROLOGOUS
10210 FOREIGN

83652 RECOMBINANT
 719877 PROTEIN#
 581093 PRODUC?
 561398 EXPRESS?
 30661 OPTIMIZ?
 L81 7785 (HETEROLOGOUS OR FOREIGN OR RECOMBINANT) (5A) (PROTEIN#) (10A) (PROD
 UC? OR EXPRESS? OR OPTIMIZ?)

FILE 'BIOTECHNO'

14199 HETEROLOGOUS
 6070 FOREIGN
 125134 RECOMBINANT
 653195 PROTEIN#
 394590 PRODUC?
 452182 EXPRESS?
 16086 OPTIMIZ?
 L82 8130 (HETEROLOGOUS OR FOREIGN OR RECOMBINANT) (5A) (PROTEIN#) (10A) (PROD
 UC? OR EXPRESS? OR OPTIMIZ?)

FILE 'WPIDS'

9977 HETEROLOGOUS
 40929 FOREIGN
 40069 RECOMBINANT
 154449 PROTEIN#
 2335750 PRODUC?
 124549 EXPRESS?
 41189 OPTIMIZ?
 L83 4754 (HETEROLOGOUS OR FOREIGN OR RECOMBINANT) (5A) (PROTEIN#) (10A) (PROD
 UC? OR EXPRESS? OR OPTIMIZ?)

TOTAL FOR ALL FILES

L84 115678 (HETEROLOGOUS OR FOREIGN OR RECOMBINANT) (5A) (PROTEIN#) (10A) (PROD
 UC? OR EXPRESS? OR OPTIMIZ?)

=> s l12 and l84

FILE 'MEDLINE'

L85 4 L1 AND L73

FILE 'SCISEARCH'

L86 3 L2 AND L74

FILE 'LIFESCI'

L87 5 L3 AND L75

FILE 'BIOTECHDS'

L88 5 L4 AND L76

FILE 'BIOSIS'

L89 2 L5 AND L77

FILE 'EMBASE'

L90 2 L6 AND L78

FILE 'HCAPLUS'

L91 5 L7 AND L79

FILE 'NTIS'

L92 0 L8 AND L80

FILE 'ESBIOBASE'

L93 3 L9 AND L81

FILE 'BIOTECHNO'

L94 2 L10 AND L82

FILE 'WPIDS'
L95 2 L11 AND L83

TOTAL FOR ALL FILES
L96 33 L12 AND L84

=> s 160 and 184
FILE 'MEDLINE'
L97 50 L49 AND L73

FILE 'SCISEARCH'
L98 47 L50 AND L74

FILE 'LIFESCI'
L99 38 L51 AND L75

FILE 'BIOTECHDS'
L100 485 L52 AND L76

FILE 'BIOSIS'
L101 55 L53 AND L77

FILE 'EMBASE'
L102 64 L54 AND L78

FILE 'HCAPLUS'
L103 165 L55 AND L79

FILE 'NTIS'
L104 0 L56 AND L80

FILE 'ESBIOBASE'
L105 42 L57 AND L81

FILE 'BIOTECHNO'
L106 74 L58 AND L82

FILE 'WPIDS'
L107 43 L59 AND L83

TOTAL FOR ALL FILES
L108 1063 L60 AND L84

=> s 1108 and coli
FILE 'MEDLINE'
249337 COLI
L109 30 L97 AND COLI

FILE 'SCISEARCH'
228507 COLI
L110 25 L98 AND COLI

FILE 'LIFESCI'
98566 COLI
L111 21 L99 AND COLI

FILE 'BIOTECHDS'
45738 COLI
L112 129 L100 AND COLI

FILE 'BIOSIS'
276667 COLI
L113 29 L101 AND COLI

FILE 'EMBASE'

```

177298 COLI
L114      34 L102 AND COLI

FILE 'HCAPLUS'
266594 COLI
L115      69 L103 AND COLI

FILE 'NTIS'
2810 COLI
L116      0 L104 AND COLI

FILE 'ESBIOBASE'
68890 COLI
L117      19 L105 AND COLI

FILE 'BIOTECHNO'
94549 COLI
L118      32 L106 AND COLI

FILE 'WPIDS'
18914 COLI
L119      8 L107 AND COLI

TOTAL FOR ALL FILES
L120      396 L108 AND COLI

=> s (l36 or l48 or l72 or l96 or l120)
FILE 'MEDLINE'
L121      51 (L25 OR L37 OR L61 OR L85 OR L109)

FILE 'SCISEARCH'
L122      43 (L26 OR L38 OR L62 OR L86 OR L110)

FILE 'LIFESCI'
L123      32 (L27 OR L39 OR L63 OR L87 OR L111)

FILE 'BIOTECHDS'
L124      133 (L28 OR L40 OR L64 OR L88 OR L112)

FILE 'BIOSIS'
L125      56 (L29 OR L41 OR L65 OR L89 OR L113)

FILE 'EMBASE'
L126      44 (L30 OR L42 OR L66 OR L90 OR L114)

FILE 'HCAPLUS'
L127      98 (L31 OR L43 OR L67 OR L91 OR L115)

FILE 'NTIS'
L128      0 (L32 OR L44 OR L68 OR L92 OR L116)

FILE 'ESBIOBASE'
L129      26 (L33 OR L45 OR L69 OR L93 OR L117)

FILE 'BIOTECHNO'
L130      43 (L34 OR L46 OR L70 OR L94 OR L118)

FILE 'WPIDS'
L131      10 (L35 OR L47 OR L71 OR L95 OR L119)

TOTAL FOR ALL FILES
L132      536 (L36 OR L48 OR L72 OR L96 OR L120)

=> s l132 not 2004-2006/py
FILE 'MEDLINE'

```

1332548 2004-2006/PY
(20040000-20069999/PY)
L133 44 L121 NOT 2004-2006/PY

FILE 'SCISEARCH'
2454856 2004-2006/PY
(20040000-20069999/PY)
L134 35 L122 NOT 2004-2006/PY

FILE 'LIFESCI'
189530 2004-2006/PY
L135 26 L123 NOT 2004-2006/PY

FILE 'BIOTECHDS'
56959 2004-2006/PY
L136 79 L124 NOT 2004-2006/PY

FILE 'BIOSIS'
1023506 2004-2006/PY
L137 50 L125 NOT 2004-2006/PY

FILE 'EMBASE'
1117159 2004-2006/PY
L138 33 L126 NOT 2004-2006/PY

FILE 'HCAPLUS'
2548350 2004-2006/PY
L139 74 L127 NOT 2004-2006/PY

FILE 'NTIS'
25986 2004-2006/PY
L140 0 L128 NOT 2004-2006/PY

FILE 'ESBIOBASE'
664275 2004-2006/PY
L141 18 L129 NOT 2004-2006/PY

FILE 'BIOTECHNO'
586 2004-2006/PY
L142 43 L130 NOT 2004-2006/PY

FILE 'WPIDS'
2489972 2004-2006/PY
L143 1 L131 NOT 2004-2006/PY

TOTAL FOR ALL FILES
L144 403 L132 NOT 2004-2006/PY

=> dup rem l144

PROCESSING COMPLETED FOR L144

L145 199 DUP REM L144 (204 DUPLICATES REMOVED)

=> d tot

L145 ANSWER 1 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI New PRO20080 polypeptides and polynucleotides, useful for treating
immune-related disorders in a mammal, e.g. systemic lupus erythematosus,
rheumatoid arthritis, systemic sclerosis, bullous skin disease, or
allergies;

recombinant protein production and
antagonist and agonist for use in disease gene therapy

AU GREWAL I; GURNEY A L; VALDEZ P A

AN 2003-20959 BIOTECHDS

PI WO 2003055440 10 Jul 2003

L145 ANSWER 2 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Novel recombinant crystallized polypeptides from Streptococcus pneumoniae useful as drug target for pathogenic bacteria, has biological activity of NH(3)-dependent NAD(+) synthetase;
 plasmid-mediated gene transfer and **expression** in Escherichia coli for **recombinant protein production** for **recombinant** vaccine and disease therapy
 AU EDWARDS A; DHARAMSI A; VEDADI M; ALAM M Z; HOUSTON S; PINDER B; NG I; LAM R; KIMBER M
 AN 2003-20545 BIOTECHDS
 PI WO 2003051916 26 Jun 2003

L145 ANSWER 3 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New peptides useful, e.g. in the treatment of or reduction of viral load of hepatitis C virus and associated conditions, e.g. liver fibrosis, necrosis, inflammation or bile duct changes;
 vector-mediated gene transfer and **expression** in host cell for **recombinant protein production**, drug screening and disease therapy
 AU JOYCE M; WILLIAMS M; HINDSGAUL O; TYRREL D L
 AN 2003-22522 BIOTECHDS
 PI WO 2003051910 26 Jun 2003

L145 ANSWER 4 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New GAVE18 polypeptide and nucleic acid molecule encoding the polypeptide, useful for preventing and treating a disease or disorder associated with aberrant expression or activity of GAVE18, e.g. asthma or rheumatoid arthritis;
recombinant protein production and agonist and antagonist for use in disease gene therapy
 AU EISHINGDRELO H; CAI J; BUSCH S J; GASSENHUBER J
 AN 2003-17738 BIOTECHDS
 PI WO 2003042399 22 May 2003

L145 ANSWER 5 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New cupiennin peptides exhibiting an antimicrobial, hemolytic or insecticidal activity, useful for preparing a composition for treating bacterial infections and tumors;
 vector-mediated gene transfer and **expression** in host cell for **recombinant protein** and insecticide **production** for use in bacterium infection and leukemia gene therapy
 AU SCHALLER J; WALZ A; NENTWIG W; KUHN-NENTWIG L
 AN 2003-16957 BIOTECHDS
 PI WO 2003035677 1 May 2003

L145 ANSWER 6 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New polynucleotide designated 205P1B5, for diagnosing and treating prostate cancer, and as probes or primers for the amplification and/or detection of 205P1B5 genes;
recombinant protein production and its encoding gene useful for gene therapy, diagnosis and prognosis
 AU CHALLITA-EID P M; RAITANO A B; FARIS M; HUBERT R S; JAKOBOVITS A
 AN 2003-14871 BIOTECHDS
 PI WO 2003020954 13 Mar 2003

L145 ANSWER 7 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New isolated polypeptide based on the neutralizing epitope of the p17 protein of HIV, useful for the diagnosis, prevention and treatment of the human acquired immune deficiency syndrome;
 plasmid-mediated gene transfer and **expression** in Escherichia coli for **recombinant** glutathione-transferase fusion **protein production** for use in HIV virus infection therapy

AU CARUSO A; FRANZONE J S
AN 2003-11714 BIOTECHDS
PI WO 2003016337 27 Feb 2003

L145 ANSWER 8 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI New UvrA and UvrB polypeptides and polynucleotides encoding the
polypeptides, useful for detecting DNA damage for diagnosing cancer,
increasing the effectiveness of drug treatment or detecting the effect of
environmental genotoxin;
recombinant protein production in
Escherichia coli useful for cancer diagnosis

AU VAN HOUTEN B; SKORVAGA M
AN 2003-11705 BIOTECHDS
PI WO 2003014324 20 Feb 2003

L145 ANSWER 9 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Novel nitrilase polypeptide, useful for making (R)- or
(S)-ethyl-4-cyano-3-hydroxybutyric acid or (R)- or (S)-mandelic acid or
(S)- or (R)-phenyl lactic acid derivative and for producing
pharmaceutical composition, and food additive;
vector-mediated recombinant protein gene transfer
and expression in host cell for use in pharmaceutical and
food industry and peptidomics

AU MADDEN M; DESANTIS G; CHAPLIN J A; WEINER D P; MILAN A; CHI E; SHORT J M;
BURK M
AN 2003-10320 BIOTECHDS
PI WO 2003000840 3 Jan 2003

L145 ANSWER 10 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI New polynucleotide, useful for manipulating plant protein quality,
improving plant growth, yield and crop productivity or grain composition
or producing plants with improved properties;
recombinant protein production via
plasmid **expression** in host cell for use in transgenic plant
construction

AU EDGERTON M D; CHOMET P S; LACCETTI L B
AN 2004-07435 BIOTECHDS
PI US 2003233670 18 Dec 2003

L145 ANSWER 11 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI New nucleic acids encoding PRO polypeptides having sequence identity to
Interleukin-17, useful for diagnosing or treating of immune related
diseases e.g. rheumatoid arthritis, thyroiditis, diabetes mellitus or
allergic rhinitis;

recombinant protein production and
antagonist and agonist for use in disease therapy and gene therapy
AU CHEN J; FILVAROFF E; FONG S; GODDARD A; GODOWSKI P; GRIMALDI J C; GURNEY
A; LI H; HILLAN K; HYMOWITZ S G; TUMAS D; STAROVASNIK M A; VANLOOKEREN M;
VANDLEN R; WATANABE C; WILLIAMS P M; WOOD W I; YANSURA D
AN 2004-05717 BIOTECHDS
PI US 2003203451 30 Oct 2003

L145 ANSWER 12 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI New genes from Staphylococcus aureus encode virulence factors designated
repressor of toxin, Rot, and Rot-like protein Rlp and are useful to
detect S. aureus in a sample;
recombinant protein production via
plasmid **expression** in host cell for in bacterium detection

AU MCNAMARA P J
AN 2004-00325 BIOTECHDS
PI US 2003171563 11 Sep 2003

L145 ANSWER 13 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI New estrogen receptor beta variant polypeptide and nucleic acid fragment,
useful in therapeutic modulation of pathophysiological estrogen signaling

(e.g. gene delivery or gene silencing), or developing pharmaceutical drug targets;

vector-mediated gene transfer and **expression** in host cell
for **recombinant protein production** and
disease therapy or gene therapy

AU QUINET E M; FAN E
AN 2004-03630 BIOTECHDS
PI US 2003162257 28 Aug 2003

L145 ANSWER 14 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Novel vascular endothelial cell growth factor-E polypeptide, useful for
treating cardiovascular or endothelial disorders;
recombinant protein production via
plasmid **expression** in host cell for use in disease therapy

AU FERRARA N; KUO S S
AN 2004-01862 BIOTECHDS
PI US 2003113870 19 Jun 2003

L145 ANSWER 15 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Composition comprising orthogonal aminoacyl-tRNA synthetase that
preferentially aminoacylates orthogonal tRNA with non-natural amino
acids, useful for incorporating non-natural amino acids into polypeptides
in vivo;

recombinant enzyme protein and vector
expression in host cell for use in non-natural amino acid
incorporation and site-selective insertion

AU SCHULTZ P; WANG L; ANDERSON J C; CHIN J W; LIU D R; MAGLIERI T J; MEGGERS
E L; MEHL R A; PASTRNAK M; SANTORO S W; ZHANG Z
AN 2004-02882 BIOTECHDS
PI US 2003108885 12 Jun 2003

L145 ANSWER 16 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI New purified nucleic acid segment encoding hyaluronic acid synthase,
useful for hyaluronic acid, and for detecting a bacterial cell that is
expressing hyaluronic synthase;

recombinant enzyme protein production
via plasmid **expression** in host cell useful for bacterium
cell detection

AU WEIGEL P H; DEANGELIS P L; PAPACONSTANTINOU J
AN 2003-28187 BIOTECHDS
PI US 2003104533 5 Jun 2003

L145 ANSWER 17 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Novel purified nucleic acid segment encoding hyaluronic acid synthase,
useful for hyaluronic acid, and for detecting a bacterial cell that is
expressing hyaluronic synthase;

vector-mediated hyaluronic-acid-synthase gene transfer and
expression in host cell for **recombinant
protein production** and cloning

AU WEIGEL P H; DEANGELIS P L; PAPACONSTANTINOU J
AN 2003-27658 BIOTECHDS
PI US 2003104415 5 Jun 2003

L145 ANSWER 18 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Novel isolated DNA98853 or DNA101848 polypeptide having homology to
members of tumor necrosis factor receptor family useful in assays to
identify proteins or molecules involved in binding interactions;

vector-mediated gene transfer and **expression** in host cell
for **recombinant protein production** and
disease therapy

AU GODDARD A; PAN J; YAN M
AN 2003-28389 BIOTECHDS
PI US 2003092044 15 May 2003

L145 ANSWER 19 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

TI New PRO nucleic acid, useful for preparing a composition for treating an immune related disease in a mammal e.g., rheumatoid arthritis, diabetes mellitus or autoimmune disease;
 vector-mediated gene transfer and **expression** in CHO cell,
 yeast or *Escherichia coli* for **recombinant protein production** for use in disease gene therapy

AU FONG S; GODDARD A; GODOWSKI P J; GRIMALDI J C; GURNEY A L; HILLAN K J; TUMAS D; WATANABE C K; WOOD W I; ZHANG Z
 AN 2003-22976 BIOTECHDS
 PI US 2003077737 24 Apr 2003

L145 ANSWER 20 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Novel isolated PRO polypeptides PRO1265, PRO1308, PRO1475, PRO4405, PRO5723, PRO7425 or PRO9940, useful for treating an immune-related disease such as rheumatoid arthritis, osteoarthritis, autoimmune hemolytic anemia;
 recombinant protein production and
 antagonist and agonist for use in disease therapy and gene therapy

AU GODDARD A; GODOWSKI P J; GURNEY A L; HILLAN K J; TUMAS D; WATANABE C K; WOOD W I
 AN 2003-27366 BIOTECHDS
 PI US 2003059437 27 Mar 2003

L145 ANSWER 21 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1031, PRO1122, PRO10272, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy;
 involving vector-mediated **recombinant protein** gene transfer and **expression** in Chinese hamster ovary, *Escherichia coli* or yeast cell for use in diagnosis, prevention, therapy and gene therapy

AU CHEN J; FILVAROFF E; FONG S; GODDARD A; GODOWSKI P J; GRIMALDI C; GURNEY A L; LI H; HILLAN K; TUMAS D; VANLOOKEREN M; VANDLEN R; WATANABE C; WILLIAMS P M; WOOD W I; YANSURA D G
 AN 2003-14221 BIOTECHDS
 PI US 2003008815 9 Jan 2003

L145 ANSWER 22 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Crystalline composition comprising hepatitis C virus (HCV) NS3/NS4A polypeptide complex, useful for determining three-dimensional structure of HCV NS3/NS4A complex, and modeling tertiary structure of related proteins;
 protein 3D structure coordinate and antagonist and agonist useful for drug screening

AU REICHERT P; PROSISE W W; TAREMI S S; YAO N; WEBER P C
 AN 2003-22442 BIOTECHDS
 PI US 6524589 25 Feb 2003

L145 ANSWER 23 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Novel Tumor Necrosis Factor (TNF) delta nucleic acid useful for assaying genetic variation and aberrations such as defects or to remediate TNF delta dysfunction, and in gene therapy;
 human **recombinant protein production** and
 its encoding gene useful for gene therapy and diagnosis

AU YU G; NI J; GENTZ R; DILLON P J
 AN 2003-14839 BIOTECHDS
 PI US 6509170 21 Jan 2003

L145 ANSWER 24 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Novel protein having D-hydantoinase or D-carbamylase activity, for manufacturing N-carbamyl-D-amino acids and D-amino acids, in chemical industry and in food additives;
 recombinant enzyme protein production
 via plasmid **expression** in host cell useful for food and pharmaceutical industry

AN 2003-19878 BIOTECHDS
PI JP 2003024074 28 Jan 2003

L145 ANSWER 25 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Polypeptide ligand of GPR8 comprising N-terminal methionine residue fused to a polypeptide having N-terminal cysteine residue, useful in the treatment of cancer and Alzheimer's disease;
recombinant protein production via
plasmid **expression** in host cell for use in disease therapy
and drug screening

AN 2003-25647 BIOTECHDS
PI JP 2003009867 14 Jan 2003

L145 ANSWER 26 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI New PRO polypeptides useful for diagnosing tumor in mammal and for producing antibodies useful in treatment of neoplastic cell growth;
recombinant protein production and
antibody for use in disease therapy and gene therapy

AU CHEN J; BAKER K P; YUAN J; GURNEY A; GODDARD A; WOOD W I
AN 2004-23473 BIOTECHDS
PI AU 2002330288 17 Apr 2003

L145 ANSWER 27 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
TI Immunogenic composition containing chimeric HIV polypeptide (p24-gp41 or p24-gp36), and test-kits for detection of antibodies raised against HIV
SO Russ., No pp. given
CODEN: RUXXE7

IN Sidorovich, I. G.; Nikolaeva, I. A.; Sheval'e, A. F.; Ignat'eva, G. A.; Korobova, S. V.; Alekseev, T. A.; Petrov, R. V.; Khaitov, R. M.

AN 2003:862724 HCAPLUS
DN 140:180118

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2214274	C2	20031020	RU 2001-122896	20010816

L145 ANSWER 28 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
TI Human stem cell growth factor mutant protein, its preparation and medical composition
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 17 pp.
CODEN: CNXXEV

IN Liu, Qingfa; Li, Jing; Hu, Huarong; Hu, Hui

AN 2005:841769 HCAPLUS
DN 143:261406

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1445239	A	20031001	CN 2002-111092	20020320

L145 ANSWER 29 OF 199 MEDLINE on STN DUPLICATE 1
TI Engineering Escherichia coli for increased productivity of **serine-rich** proteins based on proteome **profiling**

SO Applied and environmental microbiology, (2003 Oct) Vol. 69, No. 10, pp. 5772-81.

Journal code: 7605801. ISSN: 0099-2240.

AU Han Mee-Jung; Jeong Ki Jun; Yoo Jong-Shin; Lee Sang Yup
AN 2003497591 MEDLINE

L145 ANSWER 30 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
TI Quantification of the isomerization of Asp residue in recombinant human α A-crystallin by reversed-phase HPLC
SO Journal of Pharmaceutical and Biomedical Analysis (2003), 30(6), 1825-1833
CODEN: JPBADA; ISSN: 0731-7085

AU Sadakane, Yutaka; Yamazaki, Toshiaki; Nakagomi, Kazuya; Akizawa, Toshifumi; Fujii, Noriko; Tanimura, Takenori; Kaneda, Masaki; Hatanaka, Yasumaru

AN 2002:951194 HCAPLUS
DN 139:145381

L145 ANSWER 31 OF 199 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation
on STN DUPLICATE 2
TI Sulfur assimilation in soybean: Molecular cloning and characterization of
O-acetylserine (thiol) lyase (**cysteine synthase**)
SO CROP SCIENCE, (SEP-OCT 2003) Vol. 43, No. 5, pp. 1819-1827.
ISSN: 0011-183X.
AU Chronis D; Krishnan H B (Reprint)
AN 2003:774749 SCISEARCH

L145 ANSWER 32 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
TI Cloning, expression, and renaturation studies of Reteplase
SO Journal of Microbiology and Biotechnology (2003), 13(6), 989-992
CODEN: JOMBES; ISSN: 1017-7825
AU Zhao, Youchun; Wang, Ge; Kong, Yang; Zhang, Changkai
AN 2004:75941 HCAPLUS
DN 140:247840

L145 ANSWER 33 OF 199 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN
TI Molecular cloning, expression and characterization of three short chain
 α -neurotoxins from the venom of sea snake - Hydrophiinae Hydrophis
cyanocinctus Daudin.
SO Toxicon, (2003) Vol. 42, No. 7, pp. 753-761. .
Refs: 31
ISSN: 0041-0101 CODEN: TOXIA6
AU Peng L.-S.; Zhong X.-F.; Huang Y.-S.; Zhang Y.; Zheng S.-L.; Wei J.-W.; Wu
W.-Y.; Xu A.-L.
AN 2004045475 EMBASE

L145 ANSWER 34 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
TI Cloning and molecular and immunological characterisation of two new food
allergens, Cap a 2 and Lyc e 1, profilins from bell pepper (*Capsicum*
annuum) and tomato (*Lycopersicon esculentum*)
SO International Archives of Allergy and Immunology (2003), 131(4), 245-255
CODEN: IAAIEG; ISSN: 1018-2438
AU Willerroider, M.; Fuchs, H.; Ballmer-Weber, B. K.; Focke, M.; Susani, M.;
Thalhamer, J.; Ferreira, F.; Wuethrich, B.; Scheiner, O.; Breiteneder, H.;
Hoffmann-Sommergruber, K.
AN 2003:623472 HCAPLUS
DN 140:76195

L145 ANSWER 35 OF 199 MEDLINE on STN
TI A novel O-phospho-L-serine sulphydrylation reaction catalyzed by
O-acetylserine sulphydrylase from *Aeropyrum pernix* K1.
SO FEBS letters, (2003 Sep 11) Vol. 551, No. 1-3, pp. 133-8.
Journal code: 0155157. ISSN: 0014-5793.
AU Mino Koshiki; Ishikawa Kazuhiko
AN 2003424973 MEDLINE

L145 ANSWER 36 OF 199 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN DUPLICATE 3
TI Cel6A, a major exoglucanase from the cellulosome of the anaerobic fungi
Piromyces sp. E2 and *Piromyces equi*.
SO Biochimica et Biophysica Acta - Gene Structure and Expression, (9 Jul
2003) Vol. 1628, No. 1, pp. 30-39. .
Refs: 61
ISSN: 0167-4781 CODEN: BBGSD5
AU Harhangi H.R.; Freelove A.C.J.; Ubhayasekera W.; Van Dinther M.;
Steenbakkers P.J.M.; Akhmanova A.; Van Der Drift C.; Jetten M.S.M.;
Mowbray S.L.; Gilbert H.J.; Op Den Camp H.J.M.
AN 2003266875 EMBASE

L145 ANSWER 37 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New isolated nucleic acid molecule encoding a NS4 polypeptide, useful for treating a body weight disorder, e.g. obesity, anorexia, cachexia, or conditions related to obesity, e.g. polycystic ovarian disease, dermatological disorders;
 vector-mediated **recombinant protein** gene transfer and **expression** in Chinese hamster ovary cell culture, *Escherichia coli* or yeast cell for use in gene therapy
 AU GODDARD A; PAN J; WOOD W I
 AN 2003-10100 BIOTECHDS
 PI WO 2002101069 19 Dec 2002

L145 ANSWER 38 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Novel immunogenic, mutant cholera holotoxin useful for enhancing immune response of vertebrate host to antigen, comprises amino sequence of subunit A of wild-type cholera toxin;
 vector-mediated gene transfer and expression in host cell for recombinant vaccine and immunostimulant
 AU GREEN B A; HOLMES R K; JOBLING M G; ZHU D
 AN 2003-09012 BIOTECHDS
 PI WO 2002098369 12 Dec 2002

L145 ANSWER 39 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New TALL-1-binding polypeptide, useful for modulating the activity of TALL-1 and in treating, preventing or diagnosing a B-cell-mediated autoimmune diseases, cancers or lymphomas;
 vector-mediated **recombinant protein** gene transfer and **expression** in host cell for use in gene therapy
 AU MIN H; HSU H
 AN 2003-09315 BIOTECHDS
 PI WO 2002092620 21 Nov 2002

L145 ANSWER 40 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New compound containing acidic and aromatic amino acids, useful as antiviral therapy in pharmaceutical, veterinary or agricultural/horticultural applications;
 compound production and virus vector expression in host cell for use in gene therapy
 AU DASGUPTA A; DAS S; BAIDYA N
 AN 2003-07297 BIOTECHDS
 PI WO 2002083858 24 Oct 2002

L145 ANSWER 41 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Novel fusion protein for inducing human immunodeficiency virus-antigen specific IgG and IgA antibodies, has ectodomain of HIV-1 envelope glycoprotein gp41 fused to fragment of influenza virus hemagglutinin protein;
 vector-mediated gene transfer and expression in host cell for recombinant vaccine and HIV virus infection therapy
 AU WEISSENHORN W; WILEY D; MANTIS N; NEUTRA M R; KOZLOWSKI P
 AN 2003-07165 BIOTECHDS
 PI WO 2002081655 17 Oct 2002

L145 ANSWER 42 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New PRO842 polypeptides having structural homology to interleukin-8, useful for treating or diagnosing a mammal with an inflammatory disease or immune related disease, e.g. rheumatoid arthritis, osteoarthritis or allergic disease;
 vector-mediated gene transfer and **expression** in host cell for **recombinant protein** production, drug screening and gene therapy
 AU FRENCH D; GRIMALDI J C; HILIAN K J; PISABARRO M T; SCHMIDT K N; SMITH V; TUMAS D; VANDLEN R L; WATANABE C K; WILLIAMS P M; WOOD W I
 AN 2003-05386 BIOTECHDS
 PI WO 2002070706 12 Sep 2002

L145 ANSWER 43 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New product comprising a dendroaspin scaffold and a serine protease inhibitor domain ligated to the dendroaspin scaffold, useful for treating or preventing diseases associated with thrombosis, e.g. myocardial infarction, stroke;
 dendroaspin scaffold, serine protease-inhibitor domain and vector expression in host cell use in disease therapy and drug screening
 AU LU X; KAKKAR V V
 AN 2003-02235 BIOTECHDS
 PI WO 2002063017 15 Aug 2002

L145 ANSWER 44 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Novel lipase variant with reduced potential for odor generation for use in detergent compositions, comprises a parent polypeptide having lipase activity and a peptide extension attached to carboxy terminal of the polypeptide;
 recombinant protein production via
 plasmid **expression** in host cell for surfactant composition
 AU MUNK S; VIND J; BORCH K; PATKAR S A; GLAD S O S; SVENDSEN A
 AN 2003-03908 BIOTECHDS
 PI WO 2002062973 15 Aug 2002

L145 ANSWER 45 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New human PRO21074 polypeptide, useful for diagnosing, preventing, treating or monitoring the progression of cartilaginous disorders, e.g. spondyloarthropathies, rheumatoid arthritis or osteoarthritis;
 vector-mediated **recombinant protein** gene transfer
 and **expression** in Chinese hamster ovary, Escherichia coli or yeast cell culture for use in disease diagnosis, prevention, therapy and gene therapy
 AU FILVAROFF E; GODDARD A; GRIMALDI J C; WOOD W I
 AN 2003-02755 BIOTECHDS
 PI WO 2002059308 1 Aug 2002

L145 ANSWER 46 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Novel human secreted proteins and polynucleotides, useful for diagnosing and treating tumors, cardiovascular or endothelial disorders, atherosclerosis, cardiac hypertrophy, angiogenic disorders and bone disorders;
 vector-mediated **recombinant protein** gene transfer
 and **expression** in host cell for use in gene therapy,
 recombinant vaccine and nucleic acid vaccine preparation
 AU BASINSKI M B; MICANOVIC R; MILLS B J; SANKHAVARAM P R; SU E W; TSCHANG S R; VARGA G; WANG H
 AN 2002-18312 BIOTECHDS
 PI WO 2002048361 20 Jun 2002

L145 ANSWER 47 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Novel ubiquitin conjugating enzyme polypeptide isolated from activated human T cell, for screening modulators useful for treating cancer, immune disorder, lymphoproliferative disorder, neurodegenerative disorder;
 vector-mediated gene transfer, **expression** in host cell, DNA probe and antibody for **recombinant protein**
production, drug screening and disease therapy
 AU BOWEN M A; WU Y; YANG W; FINGER J N
 AN 2002-17873 BIOTECHDS
 PI WO 2002036741 10 May 2002

L145 ANSWER 48 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Novel chemokine-2 polypeptide and polynucleotide encoding the polypeptide, useful for enhancing immune response to an immunogen in a fish;
 vector-mediated **recombinant** oncogene or cytokine fusion
protein gene transfer and **expression** in host cell

for disease recombinant vaccine, prognosis, diagnosis and gene therapy
AU SUNDICK R S; LIU L; DIXON B; FUJIKI K
AN 2002-18256 BIOTECHDS
PI WO 2002036070 10 May 2002

L145 ANSWER 49 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Novel proteins and polynucleotides of secreted proteins useful for
treating various diseases e.g. rheumatoid arthritis, cancer, psoriasis,
diabetic retinopathy, arteriosclerosis, ischemia or reperfusion injury;
recombinant protein production and sense
and antisense gene use in disease therapy and gene therapy

AU SU E W; WANG H
AN 2002-17830 BIOTECHDS
PI WO 2002026801 4 Apr 2002

L145 ANSWER 50 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Polynucleotide sequences encoding human secretory proteins useful for
gene therapy of e.g. genetic deficiency disorders, cancers, and diseases
caused by intracellular parasites;
recombinant protein gene production via
plasmid **expression** in host cell, sense, antisense, agonist,
antagonist, transgenic animal, antibody, cell culture, DNA array and
polymerase chain reaction useful in disease gene therapy and drug
screening

AU STUART J; LINCOLN S E; ALTUS C M; DUFOUR G E; CHALUP M S; HILLMAN J L;
JONES A L; YU J Y; WRIGHT R J; GIETZEN D; LIU T F; YAP P E; DAHL C R;
MOMIYAMA M G; BRADLEY D L; ROHATGI S D; HARRIS B; ROSEBERRY A M; GERSTIN
E H; PERALTA C H; DAVID M H; PANZER S R; FLORES V; DAFFO A; MARWAHA R;
CHEN A J; CHANG S C; AU A P; INMAN R R
AN 2002-12753 BIOTECHDS
PI WO 2002020756 14 Mar 2002

L145 ANSWER 51 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Identifying targeting peptides useful for treating e.g. diabetes
mellitus, inflammatory diseases, cancer, or autoimmune diseases,
comprises exposing a sample to a phage display library and recovering
phage bound to the sample;
adeno-associated virus vector-mediated **recombinant
protein** gene transfer and **expression** in host cell,
Fab and humanized antibody for use in prostate cancer, Hodgkin
disease, diabetes mellitus, inflammatory disease, arthritis,
atherosclerosis, autoimmune disease, bacterium infection, virus
infection, cardiovascular disease and neurodegenerative disease
diagnosis, therapy and gene therapy

AU ARAP W; PASQUALINI R
AN 2002-13525 BIOTECHDS
PI WO 2002020722 14 Mar 2002

L145 ANSWER 52 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Monitoring 158P1H4 gene products in biological sample from patient who
has or is suspected of having cancer, useful for treating cancer,
comprises identifying presence of aberrant 158P1H4 gene products in
biological sample;
recombinant protein and monoclonal antibody
production, useful for tumor recombinant vaccine, diagnosis
and prognosis

AU CHALLITA-EID P M; HUBERT R S; RAITANO A B; AFAR D E H; LEVIN E; FARIS M;
GE W; JAKOBOVITS A
AN 2002-12096 BIOTECHDS
PI WO 2002016598 28 Feb 2002

L145 ANSWER 53 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Novel polypeptides and polynucleotides of secreted proteins useful for
treating various diseases such as multiple sclerosis, cancer, autoimmune
diseases, osteoporosis, Alzheimer's disease and Parkinson's disease;

plasmid pQE60-mediated **recombinant** IgG Fc region chimeric fusion **protein** gene transfer and **expression** in *Escherichia coli* for disease or disorder diagnosis and gene therapy

AU EDMONDS B T; MICANOVIC R; OU W; SU E W; TSCHANG S R; WANG H
AN 2002-12425 BIOTECHDS
PI WO 2002014358 21 Feb 2002

L145 ANSWER 54 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Polymer based intracellular delivery system for protein phosphatases useful for intracellular delivery of protein phosphatases for tumor therapy;
plasmid pET28b vector-mediated **recombinant protein** gene transfer and **expression** in *Escherichia coli* for hydroxypropyl methacrylamide copolymer-PP2C conjugate construction for tumor diagnosis and therapy

AU LAVI S; SATCHI-FAINARO R
AN 2002-13518 BIOTECHDS
PI WO 2002007670 31 Jan 2002

L145 ANSWER 55 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI New purified human S-acyl fatty acid synthase thioesterase-like enzyme, useful for identifying modulators of enzyme activity for treating cardiovascular disease, diabetes, obesity and hyperlipidemia;
recombinant protein gene **production** via plasmid **expression** in host cell useful in gene therapy

AU XIAO Y
AN 2002-06197 BIOTECHDS
PI WO 2002000855 3 Jan 2002

L145 ANSWER 56 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI New isolated IL-17 nucleic acids and polypeptides, useful for diagnosing and treating disorders with aberrant expression or activity of the IL-17 polypeptide, such as degenerative cartilaginous and immune-related disorders;

recombinant protein production and antagonist and agonist for use in disease therapy and gene therapy
AU CHEN J; FILVAROFF E; FONG S; FRENCH D; GODDARD A; GODOWSKI P J; GRIMALDI J C; GURNEY A L; HILLAN K J; HYMOWITZ S G; LI H; PAN J; STAROVASNIK M A; TUMAS D; VAN LOOKEREN M; VANDLEN R; WATANABE C K; WILLIAMS P M; WOOD W I; YANSURA D G
AN 2003-22452 BIOTECHDS
PI US 2002182673 5 Dec 2002

L145 ANSWER 57 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI New isolated PAL-18 polypeptide, useful for diagnosing, characterizing, and treating disease and in determining disease susceptibility;
vector-mediated **recombinant protein** gene transfer and **expression** in host cell for use in mamma cancer diagnosis and therapy

AU KINDERS R J; COREY M J
AN 2003-03761 BIOTECHDS
PI US 2002106765 8 Aug 2002

L145 ANSWER 58 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Novel isolated Apo-2DcR polypeptide useful for modulating apoptosis in mammalian cells;
plasmid pRK5-mediated **recombinant protein** gene transfer and **expression** in CHO cell, yeast, *Escherichia coli*, 293 cell and HeLa cell and hybridoma cell culture for monoclonal antibody production

AU ASHKENAZI A J; BAKER K P; CHUNTHARAPAI A; GURNEY A; KIM K J; WOOD W I
AN 2003-03758 BIOTECHDS
PI US 2002102706 1 Aug 2002

L145 ANSWER 59 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Novel Nodal and Lefty polypeptides useful for diagnosing or treating cell growth and differentiation related disorders in humans, e.g. cancer, autoimmunity, arthritis and immunosuppression;
 recombinant protein production and sense
 and antisense sequence use in gene therapy
 AU EBNER R; SOPPET D R; RUBEN S M
 AN 2003-02695 BIOTECHDS
 PI US 2002086351 4 Jul 2002

L145 ANSWER 60 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Novel antibody specific for a peptide immunogen and comprising at least one streptolysin S epitope, useful as vaccinating agent for eliciting an immune response against streptococcal infections;
 vector-mediated **recombinant protein** gene transfer
 and **expression** in host cell for use in recombinant vaccine preparation and Streptococcus sp. infection prevention and therapy
 AU DALE J B
 AN 2003-06510 BIOTECHDS
 PI US 2002086023 4 Jul 2002

L145 ANSWER 61 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Novel apoprotein antigens encoded by Mycoplasma hyopneumoniae for use in vaccines to prevent and treat diseases caused by infection with Mycoplasma hyopneumoniae in animals, especially pigs;
 recombinant protein production and sense
 and antisense sequence use in gene therapy
 AU KING K W; MADURA R A; ROSEY E L
 AN 2003-04532 BIOTECHDS
 PI EP 1245677 2 Oct 2002

L145 ANSWER 62 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New protein immobilized at solid phase by binding site, useful for detecting antibodies, comprises multiple antigen/epitope sequences for antibodies, spaced by bridge compositions so that they are exposed for antibody binding;
 recombinant protein production and
 immobilization, vector **expression** in host cell for antibody detection and virus infection testing
 AU REPKE H; BUDDE E; NICOLAUS S
 AN 2003-01093 BIOTECHDS
 PI EP 1229044 7 Aug 2002

L145 ANSWER 63 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New cysD, N, K, E and H genes from coryneform bacteria, useful, when over expressed, for increasing fermentative production of L-amino acids;
 vector plasmid pEC-XK99E-mediated **recombinant protein** gene transfer and **expression** in Escherichia coli for use in L-amino acid preparation and medicine, pharmaceutical and food industries
 AU FARWICK M; HUTHMACHER K; PFEFFERLE W; SCHISCHKA N; BATHE B
 AN 2002-16465 BIOTECHDS
 PI DE 10136986 21 Mar 2002

L145 ANSWER 64 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
 TI Cloning, characterization and biotechnological use of Physcomitrella patens proteins and enzymes involved in the synthesis of amino acids, vitamins, cofactors, nucleotides and nucleosides
 SO U.S. Pat. Appl. Publ., 107 pp.
 CODEN: USXXCO
 IN Lerchl, Jens; Renz, Andreas; Ehrhardt, Thomas; Reindl, Andreas; Cirpus, Petra; Bischoff, Friedrich; Frank, Markus; Freund, Annette; Duwenig, Elke; Schmidt, Ralf-Michael; Reski, Ralf
 AN 2002:755097 HCAPLUS
 DN 137:275028

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 2002142422	A1	20021003	US 2000-734017	20001212
L145	ANSWER 65 OF 199 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN				
TI	The sac mutants of Chlamydomonas reinhardtii reveal transcriptional and posttranscriptional control of cysteine biosynthesis				
SO	Plant Physiology, (01 DEC 2002), 130/4 (2076-2084), 47 reference(s) CODEN: PLPHAY ISSN: 0032-0889				
AU	Ravina C.G.; Chang C.-I.; Tsakrklides G.P.; McDermott J.P.; Vega J.M.; Leustek T.; Gotor C.; Davies J.P.				
AN	2002:36035203 BIOTECHNO				
L145	ANSWER 66 OF 199 MEDLINE on STN				
TI	Limits to sulfur accumulation in transgenic lupin seeds expressing a foreign sulfur-rich protein.				
SO	Plant physiology, (2002 Mar) Vol. 128, No. 3, pp. 1137-48. Journal code: 0401224. ISSN: 0032-0889.				
AU	Tabe Linda M; Droux Michel				
AN	2002160076 MEDLINE				
L145	ANSWER 67 OF 199 MEDLINE on STN DUPLICATE 4				
TI	Removal of DnaK contamination during fusion protein purifications.				
SO	Protein expression and purification, (2002 Aug) Vol. 25, No. 3, pp. 503-7. Journal code: 9101496. ISSN: 1046-5928.				
AU	Rial Daniela V; Ceccarelli Eduardo A				
AN	2002489079 MEDLINE				
L145	ANSWER 68 OF 199 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN				
TI	Recombinant human CIS2 (SOCS2) protein: Subcloning, expression , purification, and characterization.				
SO	Protein Expression and Purification, (July, 2002) Vol. 25, No. 2, pp. 305-312. print. CODEN: PEXPEJ. ISSN: 1046-5928.				
AU	Biener, Eva; Maurice, Sarah; Sandowski, Yael; Cohen, Yael; Gusakowsky, Eugene E.; Hooghe, Robert; Yoshimura, Akihiko; Livnah, Oded; Gertler, Arie [Reprint author]				
AN	2002:502157 BIOSIS				
L145	ANSWER 69 OF 199 LIFESCI COPYRIGHT 2006 CSA on STN				
TI	Secretory production of recombinant human C-reactive protein in Escherichia coli, capable of binding with phosphorylcholine, and its characterization				
SO	Biochemical and Biophysical Research Communications [Biochem. Biophys. Res. Commun.], (20020705) vol. 295, no. 1, pp. 163-166. ISSN: 0006-291X.				
AU	Tanaka, T.; Horio, T.; Matuo, Y.				
AN	2002:103909 LIFESCI				
L145	ANSWER 70 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN				
TI	Cloning and characterization of an insecticidal crystal protein gene from Bacillus thuringiensis subspecies kenyae				
SO	Journal of Genetics (2002), 81(1), 5-11 CODEN: JOGNAU; ISSN: 0022-1333				
AU	Misra, Hari S.; Khairnar, Nivedita P.; Mathur, Manjula; Vijayalakshmi, N.; Hire, Ramesh S.; Dongre, T. K.; Mahajan, S. K.				
AN	2002:773523 HCAPLUS				
DN	138:131850				
L145	ANSWER 71 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN				
TI	Isolated PRO1356, PRO617, PRO1030, PRO4302 polypeptides, useful for treating immune disorders such as thyroiditis, diabetes mellitus, allergic disease, asthma, allergic rhinitis, atopic dermatitis; retro virus vector-mediated recombinant protein				

gene transfer and **expression** in CHO cell, Escherichia coli and yeast, antagonist, agonist, antisense, DNA primer, DNA probe, monoclonal antibody, humanized antibody, singlechain antibody, expressed sequence tag, database and bioinformatic software for disease diagnosis and gene therapy

AU EATON D L; FONG S; GODDARD A; GODOWSKI P J; GRIMALDI C J; GURNEY A L;
WATANABE C K; WOOD W I; ZHANG Z
AN 2002-06124 BIOTECHDS
PI WO 2001092331 6 Dec 2001

L145 ANSWER 72 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

TI Novel subtilisin protease variants useful in cleaning
compositions, e.g. laundry **compositions** and personal
care **compositions**, has **amino acid** deletions
in defined epitope regions;
phagemid-mediated gene transfer, **expression** in Bacillus
subtilis and site-specific mutagenesis for **recombinant**
protein production and cleaner surfactant

AU Rubingh D N; Sikorski E E
AN 2001-06294 BIOTECHDS
PI WO 2001007575 1 Feb 2001

L145 ANSWER 73 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

TI New fertile transgenic maize plant comprises amino acid-elevating amount
of **expressed recombinant** inheritable gene encoding
seed storage **protein**;
plasmid pPHYGI1, plasmid pBII221 and plasmid pZ27Z10-mediated
Escherichia coli beta-glucuronidase gene transfer and
expression in maize transgenic plant for improved herbicide resistance

AU Lundquist R C; Walters D A; Kirihara J A
AN 2002-03070 BIOTECHDS
PI US 2001032344 18 Oct 2001

L145 ANSWER 74 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

TI Composition comprising mutant immunoglobulin (Ig)G molecule having
increased half-life relative to IgG, decreasing endogenous serum IgG in a
subject, comprises amino acid substitutions in Fc-hinge fragment;
vector-mediated gene transfer, **expression** in host cell and
site-directed mutagenesis for **recombinant protein**
production, vaccine and immunotherapy

AU WARD E S
AN 2002-12089 BIOTECHDS
PI US 6277375 21 Aug 2001

L145 ANSWER 75 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

TI Novel rhesus receptor having affinity for neuropeptide-Y, pancreatic
peptide-P or peptide-YY is useful for identifying compounds for treating
disorders and diseases which include cardiovascular conditions and
cerebral disorders;
vector-mediated gene transfer, **expression** in Escherichia
coli or mammal host cell for **recombinant**
protein production, drug screening and disease
therapy or prevention

AU Baez M; Yang P
AN 2001-12439 BIOTECHDS
PI US 6242251 5 Jun 2001

L145 ANSWER 76 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

TI Novel mammalian genes encoding cytokine synthesis inhibitory factor
(IL-10) and pharmaceutical compositions containing them for treating
diseases associated with cytokine imbalance;
plasmid pcD(SR-a)-mediated interleukin-10 gene transfer and
expression in COS-7 cell for **recombinant**
protein production and disease therapy

AU Mosmann T R; Moore K W; Bond M W; Vieira P J M

AN 2001-09374 BIOTECHDS
PI US 6217857 17 Apr 2001

L145 ANSWER 77 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

TI Human G protein-coupled receptors and their cDNA sequences and tissue expression profiles

SO PCT Int. Appl., 193 pp.

CODEN: PIXXD2

IN Parodi, Luis A.; Lind, Peter; Sejlitz, Torsten

AN 2001:816733 HCAPLUS

DN 135:353834

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001083553	A2	20011108	WO 2001-US14050	20010501
	WO 2001083553	A3	20020822		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001059322	A5	20011112	AU 2001-59322	20010501
	EP 1278844	A2	20030129	EP 2001-932827	20010501
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

L145 ANSWER 78 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

TI Human G protein-coupled receptors and their cDNA sequences and tissue expression profiles

SO PCT Int. Appl., 189 pp.

CODEN: PIXXD2

IN Vogeli, Gabriel

AN 2001:763192 HCAPLUS

DN 135:299596

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001077330	A2	20011018	WO 2001-US11330	20010406
	WO 2001077330	A3	20030206		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001049922	A5	20011023	AU 2001-49922	20010406
	US 2002015998	A1	20020207	US 2001-828644	20010406
	EP 1303601	A2	20030423	EP 2001-923209	20010406
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

L145 ANSWER 79 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

TI **Recombinant production of active protein in prokaryotes by refolding with reducing agent in arginine containing solution**

SO PCT Int. Appl., 57 pp.

CODEN: PIXXD2

IN Yamada, Takao; Tsuji, Isamu; Matsui, Hideki

AN 2001:747994 HCAPLUS

DN 135:300248

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001075095	A1	20011011	WO 2001-JP2712	20010330
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2404567	AA	20011011	CA 2001-2404567	20010330
	AU 2001044647	A5	20011015	AU 2001-44647	20010330
	JP 2001342198	A2	20011211	JP 2001-99706	20010330
	EP 1273655	A1	20030108	EP 2001-917667	20010330
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003120042	A1	20030626	US 2002-240295	20020927

L145 ANSWER 80 OF 199 LIFESCI COPYRIGHT 2006 CSA on STN
 TI Characterization of the Enzymatic Component of the ADP-Ribosyltransferase Toxin CDTa from Clostridium difficile
 SO Infection and Immunity [Infect. Immun.], (20011000) vol. 69, no. 10, pp. 6004-6011.
 ISSN: 0019-9567.
 AU Guelke, I.; Pfeifer, G.; Liese, J.; Fritz, M.; Hofmann, F.; Aktories, K.; Barth, H.*
 AN 2001:110094 LIFESCI

L145 ANSWER 81 OF 199 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN
 TI Production of β -(pyrazol-1-yl)-L-alanine from L-serine and pyrazol using recombinant Escherichia coli cells expressing serine acetyltransferase and O-acetylserine sulphydrylase-A
 SO Biotechnology Letters, (2001), 23/24 (2051-2055), 11 reference(s)
 CODEN: BILED3 ISSN: 0141-5492
 AU Mino K.; Yamanoue T.; Ohno K.; Sakiyama T.; Eisaki N.; Matsuyama A.; Nakanishi K.
 AN 2001:34073241 BIOTECHNO

L145 ANSWER 82 OF 199 MEDLINE on STN DUPLICATE 5
 TI cDNA cloning and molecular identification of the major oyster allergen from the Pacific oyster Crassostrea gigas.
 SO Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, (2001 Aug) Vol. 31, No. 8, pp. 1287-94.
 Journal code: 8906443. ISSN: 0954-7894.
 AU Leung P S; Chu K H
 AN 2001487002 MEDLINE

L145 ANSWER 83 OF 199 LIFESCI COPYRIGHT 2006 CSA on STN
 TI Rapid Isolation of Monoclonal Antibodies. Monitoring Enzymes in the Phytochelatin Synthesis Pathway
 SO Plant Physiology [Plant Physiol.], (20011100) vol. 127, no. 3, pp. 711-719.
 ISSN: 0032-0889.
 AU Li, Y.; Kandasamy, M.K.; Meagher*, R.B.
 AN 2002:8776 LIFESCI

L145 ANSWER 84 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Potentiating immune responses to antigens using specified Mycobacterium tuberculosis proteins;
recombinant protein production for
interleukin-12 and interferon-gamma
 AU Skeiky Y
 AN 2000-12157 BIOTECHDS

PI WO 2000039301 6 Jul 2000

L145 ANSWER 85 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI New polynucleotides encoding proteins, with e.g. nutritional, chemokine,
immune stimulating or suppressing, hematopoiesis regulating, tissue
growth, tumor inhibition or antiinflammatory activity;
human brain, kidney, blood, bladder, etc. **recombinant**
protein production via vector-mediated gene transfer
and **expression** in mammal host cell for disease therapy
AU Jacobs K; McCoy J M; LaVallie E R; Collins-Racie L A; Evans C; Merberg D;
Treacy M; Agostino M J; Steininger II R J; Spaulding V; Wong G G; Clark H
F; Fechtel K
AN 2000-06517 BIOTECHDS
PI WO 2000009552 24 Feb 2000

L145 ANSWER 86 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI New polynucleotides encoding human retinoid binding protein especially
useful for diagnosing, treating and preventing cancer, inflammation and
disorders associated with retinoid metabolism;
recombinant protein production via
vector plasmid pBluescript-mediated gene transfer and
expression in *Escherichia coli* for diagnosis,
therapy and gene therapy
AU Bandman O; Guegler K J; Shah P
AN 2000-07809 BIOTECHDS
PI US 6046027 4 Apr 2000

L145 ANSWER 87 OF 199 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
TI An isolated polypeptide conserved in proteobacterial extracellular domains
used in the treatment and prevention of bacterial infections.
PI WO 2000061165 A1 20001019 (200062)* EN 83 A61K038-00
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: JP US
IN LUPAS, A N

L145 ANSWER 88 OF 199 MEDLINE on STN DUPLICATE 6
TI Characterization of O-acetyl-L-serine sulfhydrylase purified from an
alkaliphilic bacterium.
SO Bioscience, biotechnology, and biochemistry, (2000 Nov) Vol. 64, No. 11,
pp. 2352-9.
Journal code: 9205717. ISSN: 0916-8451.
AU Sugihara Y; Yamagata S; Mizuno Y; Ezaki T
AN 2001138968 MEDLINE

L145 ANSWER 89 OF 199 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN DUPLICATE 7
TI Recombinant decorsin: Dynamics of the RGD recognition site.
SO Protein Science, (August, 2000) Vol. 9, No. 8, pp. 1428-1438. print.
ISSN: 0961-8368.
AU Krezel, Andrzej M. [Reprint author]; Ulmer, Jana S.; Wagner, Gerhard;
Lazarus, Robert A.
AN 2000:424640 BIOSIS

L145 ANSWER 90 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
TI Cloning and recombinant expression of insulin receptor ligand-binding
domains
SO Shengwu Huaxue Yu Shengwu Wuli Xuebao (2000), 32(6), 627-632
CODEN: SHWPAU; ISSN: 0582-9879
AU Zhang, Hong; Qiao, Zhi-Song; Feng, You-Min
AN 2001:3783 HCAPLUS
DN 135:205742

L145 ANSWER 91 OF 199 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN
TI Expression of a bacterial **serine** acetyltransferase in
transgenic potato plants leads to increased **levels** of cysteine

and glutathione

SO Plant Journal, (2000), 22/4 (335-343), 54 reference(s)
CODEN: PLJUJED ISSN: 0960-7412

AU Harms K.; Von Ballmoos P.; Brunold C.; Hofgen R.; Hesse H.
AN 2000:30400021 BIOTECHNO

L145 ANSWER 92 OF 199 MEDLINE on STN DUPLICATE 8

TI Molecular cloning and functional characterization of cDNAs encoding
cysteine synthase and serine acetyltransferase
that may be responsible for high cellular cysteine content in
Allium tuberosum.

SO Gene, (2000 Oct 31) Vol. 257, No. 2, pp. 269-77.
Journal code: 7706761. ISSN: 0378-1119.

AU Urano Y; Manabe T; Noji M; Saito K
AN 2001061875 MEDLINE

L145 ANSWER 93 OF 199 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation
on STN

TI Regulation of sulfate transport and synthesis of sulfur-containing amino
acids

SO CURRENT OPINION IN PLANT BIOLOGY, (JUN 2000) Vol. 3, No. 3, pp. 188-195.
ISSN: 1369-5266.

AU Saito K (Reprint)
AN 2000:377187 SCISEARCH

L145 ANSWER 94 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

TI Extracellular Expression, Purification, and Characterization of a Winter
Flounder Antifreeze Polypeptide from Escherichia coli

SO Protein Expression and Purification (2000), 18(2), 175-181
CODEN: PEXPEJ; ISSN: 1046-5928

AU Tong, Li; Lin, Qingsong; Wong, W. K. Raymond; Ali, Asma; Lim, Daniel;
Sung, Wing L.; Hew, Choy L.; Yang, Daniel S. C.

AN 2000:127507 HCAPLUS
DN 132:344551

L145 ANSWER 95 OF 199 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN DUPLICATE 9

TI Characterization of Api g 1.0201, a new member of the Api g 1 family of
celery allergens.

SO International Archives of Allergy and Immunology, (2000) Vol. 122, No. 2,
pp. 115-123. .
Refs: 49
ISSN: 1018-2438 CODEN: IAAIEG

AU Hoffmann-Sommergruber K.; Ferris R.; Pec M.; Radauer C.; O'Riordain G.;
Laimer da Camara Machado M.; Scheiner O.; Breiteneder H.

AN 2000238357 EMBASE

L145 ANSWER 96 OF 199 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN DUPLICATE 10

TI Trichomonas vaginalis: Characterization, expression, and phylogenetic
analysis of a carbamate kinase gene sequence.

SO Experimental Parasitology, (2000) Vol. 95, No. 1, pp. 54-62. .
Refs: 42
ISSN: 0014-4894 CODEN: EXPAAA

AU Minotto L.; Edwards M.R.; Bagnara A.S.
AN 2000225429 EMBASE

L145 ANSWER 97 OF 199 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN

TI O-acetylserine sulphydrylase from Methanosarcina thermophila

SO Journal of Bacteriology, (2000), 182/1 (45-50), 49 reference(s)
CODEN: JOBAAAY ISSN: 0021-9193

AU Borup B.; Ferry J.G.
AN 2000:30004556 BIOTECHNO

L145 ANSWER 98 OF 199 MEDLINE on STN DUPLICATE 11

TI Sequence polymorphism of the group 1 allergen of Bermuda grass pollen.
SO Clinical and experimental allergy : journal of the British Society for
Allergy and Clinical Immunology, (1999 Apr) Vol. 29, No. 4, pp. 488-96.
Journal code: 8906443. ISSN: 0954-7894.
AU Chang Z N; Peng H J; Lee W C; Chen T S; Chua K Y; Tsai L C; Chi C W; Han S
H
AN 1999220064 MEDLINE

L145 ANSWER 99 OF 199 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation
on STN DUPLICATE 12
TI Physicochemical studies of hepatitis A virus recombinant proteins:
interaction with monolayers as membrane models
SO MATERIALS SCIENCE & ENGINEERING C-BIOMIMETIC AND SUPRAMOLECULAR SYSTEMS,
(1 DEC 1999) Vol. 8-9, Sp. iss. SI, pp. 481-485.
ISSN: 0928-4931.
AU Carmona M A; Alsina M A; Pinto R M; Sanchez G; Guix S; Pujol M (Reprint)
AN 2000:40699 SCISEARCH

L145 ANSWER 100 OF 199 MEDLINE on STN DUPLICATE 13
TI cDNA cloning and heterologous expression of coniferin beta-glucosidase.
SO Plant molecular biology, (1999 May) Vol. 40, No. 2, pp. 365-72.
Journal code: 9106343. ISSN: 0167-4412.
AU Dharmawardhana D P; Ellis B E; Carlson J E
AN 1999339259 MEDLINE

L145 ANSWER 101 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
TI Designing recombinant spider silk proteins to control assembly
SO International Journal of Biological Macromolecules (1999), 24(2,3),
265-270
CODEN: IJBMDR; ISSN: 0141-8130
AU Winkler, Stefan; Szela, Sandra; Avtges, Peter; Valluzzi, Regina;
Kirschner, Daniel A.; Kaplan, David
AN 1999:249204 HCAPLUS
DN 131:98924

L145 ANSWER 102 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Compositions containing 65 kDa heat shock protein polypeptides;
human or Mycobacterium tuberculosis recombinant heat shock
protein-65 preparation by expression in Escherichia
coli, used for insulin dependent diabetes mellitus therapy
AU Cohen I R; Elias D; Markovits D
AN 1998-09496 BIOTECHDS
PI US 5780034 14 Jul 1998

L145 ANSWER 103 OF 199 MEDLINE on STN DUPLICATE 14
TI Identification, purification, and characterization of transpeptidase and
glycosyltransferase domains of Streptococcus pneumoniae penicillin-binding
protein 1a.
SO Journal of bacteriology, (1998 Nov) Vol. 180, No. 21, pp. 5652-9.
Journal code: 2985120R. ISSN: 0021-9193.
AU Di Guilmi A M; Mouz N; Andrieu J P; Hoskins J; Jaskunas S R; Gagnon J;
Dideberg O; Vernet T
AN 1999008999 MEDLINE

L145 ANSWER 104 OF 199 MEDLINE on STN DUPLICATE 15
TI Matrix-assisted laser desorption/ionization and electrospray ionization
mass spectrometry analysis of blue copper proteins. Azurin and mavecyanin.
SO Rapid communications in mass spectrometry : RCM, (1998) Vol. 12, No. 23,
pp. 1967-71.
Journal code: 8802365. ISSN: 0951-4198.
AU Fukuo T; Kubota N; Kataoka K; Nakai M; Suzuki S; Arakawa R
AN 1999058891 MEDLINE

L145 ANSWER 105 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
TI '98 Escherichia coli SWISS-2DPAGE database update

SO Electrophoresis (1998), 19(11), 1960-1971
 CODEN: ELCTDN; ISSN: 0173-0835

AU Tonella, Luisa; Walsh, Brad J.; Sanchez, Jean-Charles; Ou, Keli; Wilkins, Marc R.; Tyler, Margaret; Frutiger, Severine; Gooley, Andrew A.; Pescaru, Ioana; Appel, Ron D.; Yan, Jun X.; Bairoch, Amos; Hoogland, Christine; Morch, Fabienne S.; Hughes, Graham J.; Williams, Keith L.; Hochstrasser, Denis F.

AN 1998:635865 HCAPLUS
 DN 129:299940

L145 ANSWER 106 OF 199 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 16

TI **Expression of recombinant psoriasis-associated fatty acid binding protein in Escherichia coli: Gel electrophoretic characterization, analysis of binding properties and comparison with human serum albumin.**

SO Electrophoresis, (1998) Vol. 19, No. 10, pp. 1793-1802. .
 Refs: 68
 ISSN: 0173-0835 CODEN: ELCTDN

AU Vorum H.; Madsen P.; Svendsen I.; Celis J.E.; Honore B.

AN 1998290389 EMBASE

L145 ANSWER 107 OF 199 LIFESCI COPYRIGHT 2006 CSA on STN

TI High-fidelity translation of recombinant human hemoglobin in *Escherichia coli*

SO APPL. ENVIRON. MICROBIOL., (19980500) vol. 64, no. 5, pp. 1589-1593.
 ISSN: 0099-2240.

AU Weickert, M.J.; Apostol, I.

AN 1998:74654 LIFESCI

L145 ANSWER 108 OF 199 MEDLINE on STN DUPLICATE 17

TI Complexes of serine acetyltransferase and isozymes of **cysteine synthase** in spinach leaves.

SO Bioscience, biotechnology, and biochemistry, (1998 May) Vol. 62, No. 5, pp. 947-52.
 Journal code: 9205717. ISSN: 0916-8451.

AU Zhu X; Yamaguchi T; Masada M

AN 1998312031 MEDLINE

L145 ANSWER 109 OF 199 LIFESCI COPYRIGHT 2006 CSA on STN DUPLICATE 18

TI Identification and purification of O-acetyl-l-serine sulphhydrylase in *Penicillium chrysogenum*

SO Applied Microbiology and Biotechnology [Appl. Microbiol. Biotechnol.], (19980000) vol. 50, no. 6, pp. 663-668.
 ISSN: 0175-7598.

AU Oestergaard, S.; Theilgaard, H.B.Aa.; Nielsen, J.

AN 2002:104232 LIFESCI

L145 ANSWER 110 OF 199 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 19

TI Effect of coordinated addition of specific amino acids on the synthesis of recombinant glucose isomerase

SO ENZYME AND MICROBIAL TECHNOLOGY, (15 DEC 1998) Vol. 23, No. 7-8, pp. 506-510.
 ISSN: 0141-0229.

AU Paul A; Bhosale S H; Maity T K; Deshpande V V (Reprint)

AN 1998:810236 SCISEARCH

L145 ANSWER 111 OF 199 MEDLINE on STN DUPLICATE 20

TI Purification and characterization of a novel **cysteine synthase** isozyme from spinach hydrated seeds.

SO Bioscience, biotechnology, and biochemistry, (1998 Mar) Vol. 62, No. 3, pp. 501-7.
 Journal code: 9205717. ISSN: 0916-8451.

AU Yamaguchi T; Zhu X; Masada M

AN 1998233272 MEDLINE

L145 ANSWER 112 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

TI Cloning and immunological characterization of the allergen Hel a 2 (profilin) from sunflower pollen

SO Molecular Immunology (1998), 35(8), 469-478
CODEN: MOIMD5; ISSN: 0161-5890

AU Asturias, J. A.; Arilla, M. C.; Gomez-Bayon, N.; Aguirre, M.; Martinez, A.; Palacios, R.; Martinez, J.

AN 1998:686237 HCAPLUS

DN 130:65146

L145 ANSWER 113 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

TI Characterization of recombinant Mercurialis annua major allergen Mer a 1 (profilin)

SO Journal of Allergy and Clinical Immunology (1998), 101(3), 363-370
CODEN: JACIBY; ISSN: 0091-6749

AU Vallverdu, Angel; Asturias, Juan A.; Arilla, Carmen; Gomez-Bayon, Nuria; Martinez, Alberto; Martinez, Jorge; Palacios, Ricardo

AN 1998:228146 HCAPLUS

DN 129:40061

L145 ANSWER 114 OF 199 LIFESCI COPYRIGHT 2006 CSA on STN

TI Biosynthesis and Isolation of the **Recombinant Protein** for the **Production** of Genetically Engineered Human Proinsulin

SO Applied Biochemistry and Microbiology [Appl. Biochem. Microbiol.], (19980600) vol. 34, no. 3, pp. 266-271.
ISSN: 0003-6838.

AU Ivankin, A.N.; Mitaleva, S.I.; Neklyudov, A.D.

AN 1999:33251 LIFESCI

L145 ANSWER 115 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

TI Cloning, expression in Escherichia coli and characterization of Arabidopsis thaliana UMP/CMP-kinase; glutathione-transferase and uridine-monophosphate/cytidine-monophosphate-kinase **recombinant fusion protein** preparation by vector plasmid pGEX-4T-3 **expression**

SO Plant Physiol.; (1998) 117, 1, 245-54
CODEN: PLPHAY ISSN: 0032-0889

AU Zhou L; Lacoute F; *Thornburg R

AN 1998-08333 BIOTECHDS

L145 ANSWER 116 OF 199 MEDLINE on STN DUPLICATE 21

TI Interactions between serine acetyltransferase and O-acetylserine (thiol) lyase in higher plants--structural and kinetic properties of the free and bound enzymes.

SO European journal of biochemistry / FEBS, (1998 Jul 1) Vol. 255, No. 1, pp. 235-45.
Journal code: 0107600. ISSN: 0014-2956.

AU Droux M; Ruffet M L; Douce R; Job D

AN 1998355673 MEDLINE

L145 ANSWER 117 OF 199 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE

AN 1998035749 ESBIOWASE

TI Human glutathione transferase A4-4: An Alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid peroxidation

AU Hubatsch I.; Ridderstrom M.; Mannervik B.

CS B. Mannervik, Department of Biochemistry, Uppsala University, Biomedical Center, Box 576, S-751 23 Uppsala, Sweden.

SO Biochemical Journal, (15 FEB 1998), 330/1 (175-179), 33 reference(s)
CODEN: BIJOAK ISSN: 0264-6021

DT Journal; Article

CY United Kingdom

LA English
SL English

L145 ANSWER 118 OF 199 MEDLINE on STN DUPLICATE 23
TI Regulation of the O-acetyl-L-serine(thiol)lyase activity in *Monoraphidium braunii*.
SO Journal of physiology and biochemistry, (1998 Sep) Vol. 54, No. 3, pp. 141-8.
Journal code: 9812509. ISSN: 1138-7548.
AU Gonzalez-Arroyo J G; Vega J M; Perez-Castineira J R
AN 1999231562 MEDLINE

L145 ANSWER 119 OF 199 MEDLINE on STN DUPLICATE 24
TI Purification and characterization of recombinant spider silk expressed in *Escherichia coli*.
SO Applied microbiology and biotechnology, (1998 Jan) Vol. 49, No. 1, pp. 31-8.
Journal code: 8406612. ISSN: 0175-7598.
AU Arcidiacono S; Mello C; Kaplan D; Cheley S; Bayley H
AN 1998148687 MEDLINE

L145 ANSWER 120 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
TI Nucleic acid and amino acid sequences relating to *Helicobacter pylori* and vaccine compositions
SO PCT Int. Appl., 1144 pp.
CODEN: PIXXD2
IN Smith, Douglas; Alm, Richard A.
AN 1997:679205 HCAPLUS
DN 127:355960

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9737044	A1	19971009	WO 1997-US5223	19970327
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, US, US, US, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2248985	AA	19971009	CA 1997-2248985	19970327
	AU 9725984	A1	19971022	AU 1997-25984	19970327
	AU 726892	B2	20001123		
	ZA 9702715	A	19980625	ZA 1997-2715	19970327
	EP 901530	A1	19990317	EP 1997-917731	19970327
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1220703	A	19990623	CN 1997-195113	19970327
	BR 9708456	A	19990803	BR 1997-8456	19970327
	JP 2000501621	T2	20000215	JP 1997-529649	19970327
	NZ 332565	A	20000327	NZ 1997-332565	19970327
	NO 9804517	A	19981125	NO 1998-4517	19980928

L145 ANSWER 121 OF 199 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN
TI Cystalysin, a 46-kilodalton cysteine desulphhydrase from *Treponema denticola*, with hemolytic and hemoxidative activities
SO Infection and Immunity, (1997), 65/8 (3231-3238), 61 reference(s)
CODEN: INFIBR ISSN: 0019-9567
AU Chu L.; Ebersole J.L.; Kurzban G.P.; Holt S.C.
AN 1997:27342404 BIOTECHNO

L145 ANSWER 122 OF 199 MEDLINE on STN DUPLICATE 25
TI A novel cDNA clone of *Schistosoma japonicum* encoding the 34,000 Dalton eggshell precursor protein.
SO International journal for parasitology, (1997 Jul) Vol. 27, No. 7, pp.

811-7.

Journal code: 0314024. ISSN: 0020-7519.

AU Sugiyama H; Kawanaka M; Kameoka Y; Nakamura M
AN 97425534 MEDLINE

L145 ANSWER 123 OF 199 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation
on STN

TI Addition of acetaldehyde to the N-terminus of a recombinant Schistosoma
mansoni glutathione S-transferase upon high-level expression in
Saccharomyces cerevisiae

SO EUROPEAN JOURNAL OF BIOCHEMISTRY, (1 MAY 1997) Vol. 245, No. 3, pp.
589-599.
ISSN: 0014-2956.

AU Roecklin D (Reprint); Klarskov K; Cavallini B; Sabatie J; Bouchon B; Loew
D; VanDorsselaer A; Bischoff R

AN 1997:374333 SCISEARCH

L145 ANSWER 124 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

TI Cloning and expression of the panallergen profilin and the major allergen
(Ole e 1) from olive tree pollen

SO Journal of Allergy and Clinical Immunology (1997), 100(3), 365-372
CODEN: JACIBY; ISSN: 0091-6749

AU Asturias, Juan A.; Arilla, M. Carmen; Gomez-Bayon, Nuria; Martinez, Jorge;
Martinez, Alberto; Palacios, Ricardo

AN 1997:669380 HCAPLUS

DN 127:330283

L145 ANSWER 125 OF 199 MEDLINE on STN

TI The inhibitory effect of recombinant human C3 fragment on murine endotoxic
shock.

SO Zhonghua yi xue za zhi, (1997 Apr) Vol. 77, No. 4, pp. 274-7.
Journal code: 7511141. ISSN: 0376-2491.

AU Liang H; Song Q; Zhang Y

AN 1998259216 MEDLINE

L145 ANSWER 126 OF 199 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
reserved on STN DUPLICATE 26

TI Molecular bases of hexokinase deficiency.

SO Biochimica et Biophysica Acta - Molecular Basis of Disease, (1997) Vol.
1360, No. 3, pp. 211-221. .
Refs: 29

ISSN: 0925-4439 CODEN: BBADEX

AU Bianchi M.; Crinelli R.; Serafini G.; Giammarini C.; Magnani M.

AN 97161612 EMBASE

L145 ANSWER 127 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

TI Dependence of recombinant protein expression
on amino acid composition

SO Book of Abstracts, 213th ACS National Meeting, San Francisco, April 13-17
(1997), BIOC-148 Publisher: American Chemical Society, Washington, D. C.
CODEN: 64AOAA

AU Lamouse-Smith, Araba A. K.; Wang, Daniel I. C.

AN 1997:230214 HCAPLUS

L145 ANSWER 128 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

TI Recombinant gilthead seabream (Sparus aurata) insulin-like growth
factor-I: subcloning, expression in Escherichia coli,
purification and characterization

SO Journal of Endocrinology (1997), 153(1), 139-150
CODEN: JOENAK; ISSN: 0022-0795

AU Fine, M.; Amuly, R.; Sandowski, Y.; Marchant, T. A.; Chan, S. J.; Gertler,
A.; Funkenstein, B.

AN 1997:280137 HCAPLUS

DN 127:3151

L145 ANSWER 129 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Epitope tag-antibody combination useful for the detection of protein
 expression in prokaryotic and eukaryotic cells;
 birch pollen profilin DNA sequence insertion in DNA cassette in
 plasmid pMal/BiPro for Escherichia coli and plasmid
 pcDNA3/BiPro for e.g. mammal cell culture
 SO BioTechniques; (1997) 23, 1, 96-97
 CODEN: BTNQDO ISSN: 0736-6205
 AU Ruediger M; Jockusch B M; *Rothkegel M
 AN 1997-09735 BIOTECHDS

L145 ANSWER 130 OF 199 MEDLINE on STN DUPLICATE 27
 TI **Production** of plant non-protein amino acids by
recombinant enzymes of sequential biosynthetic reactions in
 bacteria.
 SO Biological & pharmaceutical bulletin, (1997 Jan) Vol. 20, No. 1, pp.
 47-53.
 Journal code: 9311984. ISSN: 0918-6158.
 AU Saito K; Kimura N; Ikegami F; Noji M
 AN 97165913 MEDLINE

L145 ANSWER 131 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
 TI Cross-species protein identification using **amino acid**
composition, peptide mass fingerprinting, isoelectric point and
 molecular mass: a theoretical evaluation
 SO Journal of Theoretical Biology (1997), 186(1), 7-15
 CODEN: JTBIAP; ISSN: 0022-5193
 AU Wilkins, Marc R.; Williams, Keith L.
 AN 1997:382428 HCAPLUS
 DN 127:78195

L145 ANSWER 132 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Dependence of **recombinant protein expression**
 on **amino acid composition**;
 as determined in Escherichia coli (conference abstract)
 SO Abstr.Pap.Am.Chem.Soc.; (1997) 213 Meet., Pt.1, BIOT147
 CODEN: ACSRAL ISSN: 0065-7727
 American Chemical Society, 213th ACS National Meeting, San Francisco, CA,
 13-17 April, 1997.
 AU Lamouse-Smith A A K; Wang D I C
 AN 1997-12036 BIOTECHDS

L145 ANSWER 133 OF 199 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
 reserved on STN DUPLICATE 29
 TI Role of electrostatic interactions in defining the potency of neurotoxin
 B-IV from Cerebratulus lacteus.
 SO Journal of Biological Chemistry, (1996) Vol. 271, No. 47, pp. 29752-29758.
 ISSN: 0021-9258 CODEN: JBCHA3
 AU Wen P.H.; Blumenthal K.M.
 AN 96354914 EMBASE

L145 ANSWER 134 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Expression and characterization of rat pancreatic secretory trypsin
 inhibitor-I and -II in Saccharomyces cerevisiae, and simple purification
 by affinity chromatography;
 gene cloning
 SO J.Ferment.Bioeng.; (1996) 82, 5, 444-47
 CODEN: JFBIEX ISSN: 0922-338X
 AU Katoh T; Horii T; Fujiwara T; Kikuchi N; Shin M; Nagata K; Yoshida N;
 Miyasaka K; Funakoshi A
 AN 1997-01856 BIOTECHDS

L145 ANSWER 135 OF 199 MEDLINE on STN DUPLICATE 30
 TI Isolation, characterization and expression of cDNA clones encoding a

mitochondrial malate translocator from *Panicum miliaceum* L.
SO Plant molecular biology, (1996 Jan) Vol. 30, No. 1, pp. 51-64.
Journal code: 9106343. ISSN: 0167-4412.
AU Taniguchi M; Sugiyama T
AN 96197398 MEDLINE

L145 ANSWER 136 OF 199 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation
on STN
TI Enhanced alpha-amylase production in recombinant *Bacillus brevis* by
fed-batch culture with amino acid control
SO BIOTECHNOLOGY AND BIOENGINEERING, (5 JAN 1996) Vol. 49, No. 1, pp. 36-44.
ISSN: 0006-3592.
AU Park Y S (Reprint); Dohjima T; Okabe M
AN 1996:1771 SCISEARCH

L145 ANSWER 137 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
TI **Recombinant protein production:**
Opportunities for peptide research.
SO Book of Abstracts, 211th ACS National Meeting, New Orleans, LA, March
24-28 (1996), I&EC-019 Publisher: American Chemical Society, Washington,
D. C.
CODEN: 62PIAJ
AU Better, Marc; Nolan, Patricia; Lin, Po-Heng; Gavit, Patrick
AN 1996:219538 HCAPLUS

L145 ANSWER 138 OF 199 MEDLINE on STN DUPLICATE 31
TI Construction, cloning, and expression of synthetic genes encoding spider
dragline silk.
SO Biochemistry, (1995 Aug 29) Vol. 34, No. 34, pp. 10879-85.
Journal code: 0370623. ISSN: 0006-2960.
AU Prince J T; McGrath K P; DiGirolamo C M; Kaplan D L
AN 95391665 MEDLINE

L145 ANSWER 139 OF 199 MEDLINE on STN DUPLICATE 32
TI Expression of bacterial cysteine biosynthesis genes in transgenic mice and
sheep: toward a new in vivo amino acid biosynthesis pathway and improved
wool growth.
SO Transgenic research, (1995 Mar) Vol. 4, No. 2, pp. 87-104.
Journal code: 9209120. ISSN: 0962-8819.
AU Bawden C S; Sivaprasad A V; Verma P J; Walker S K; Rogers G E
AN 95218849 MEDLINE

L145 ANSWER 140 OF 199 MEDLINE on STN DUPLICATE 33
TI Cloning and heterologous expression of a gene encoding an alkane-induced
extracellular protein involved in alkane assimilation from *Pseudomonas*
.
SO Applied and environmental microbiology, (1994 Oct) Vol. 60, No. 10, pp.
3679-87.
Journal code: 7605801. ISSN: 0099-2240.
AU Hardegger M; Koch A K; Ochsner U A; Fiechter A; Reiser J
AN 95077367 MEDLINE

L145 ANSWER 141 OF 199 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation
on STN DUPLICATE 34
TI ENZYMATIC-SYNTHESIS OF NONPROTEIN BETA-SUBSTITUTED ALANINES AND SOME
HIGHER HOMOLOGS IN PLANTS
SO PHYTOCHEMISTRY, (MAR 1994) Vol. 35, No. 5, pp. 1089-1104.
ISSN: 0031-9422.
AU IKEGAMI F (Reprint); MURAKOSHI I
AN 1994:269740 SCISEARCH

L145 ANSWER 142 OF 199 MEDLINE on STN DUPLICATE 35
TI Evolutionary relationships among pyridoxal-5'-phosphate-dependent enzymes.
Regio-specific alpha, beta and gamma families.
SO European journal of biochemistry / FEBS, (1994 Feb 1) Vol. 219, No. 3, pp.

953-60.

Journal code: 0107600. ISSN: 0014-2956.

AU Alexander F W; Sandmeier E; Mehta P K; Christen P
AN 94155902 MEDLINE

L145 ANSWER 143 OF 199 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation
on STN

TI PURIFICATION AND KINETIC-PROPERTIES OF SERINE ACETYLTRANSFERASE FREE OF
O-ACETYL SERINE (THIOL) LYASE FROM SPINACH-CHLOROPLASTS

SO PLANT PHYSIOLOGY, (FEB 1994) Vol. 104, No. 2, pp. 597-604.
ISSN: 0032-0889.

AU RUFFET M L (Reprint); DROUX M; DOUCE R
AN 1994:145583 SCISEARCH

L145 ANSWER 144 OF 199 MEDLINE on STN DUPLICATE 36

TI Isolation and characterization of a mouse amelogenin expressed in
Escherichia coli.

SO Calcified tissue international, (1994 Apr) Vol. 54, No. 4, pp. 312-9.
Journal code: 7905481. ISSN: 0171-967X.

AU Simmer J P; Lau E C; Hu C C; Aoba T; Lacey M; Nelson D; Zeichner-David M;
Snead M L; Slavkin H C; Fincham A G
AN 94340455 MEDLINE

L145 ANSWER 145 OF 199 MEDLINE on STN DUPLICATE 37

TI The 24 kDa outer envelope membrane protein from spinach chloroplasts:
molecular cloning, in vivo expression and import pathway of a protein with
unusual properties.

SO Plant molecular biology, (1994 May) Vol. 25, No. 2, pp. 167-77.
Journal code: 9106343. ISSN: 0167-4412.

AU Fischer K; Weber A; Arbing B; Brink S; Eckerskorn C; Flugge U I
AN 94289642 MEDLINE

L145 ANSWER 146 OF 199 MEDLINE on STN DUPLICATE 38

TI Purification of recombinant human granulocyte-macrophage
colony-stimulating factor from the inclusion bodies produced by
transformed Escherichia coli cells.

SO Journal of chromatography. A, (1994 Sep 9) Vol. 679, No. 1, pp. 67-83.
Journal code: 9318488. ISSN: 0021-9673.

AU Belew M; Zhou Y; Wang S; Nystrom L E; Janson J C
AN 95039693 MEDLINE

L145 ANSWER 147 OF 199 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN

TI Purification, characterization, and biosynthesis of margatoxin, a
component of Centruroides margaritatus venom that selectively inhibits
voltage-dependent potassium channels

SO Journal of Biological Chemistry, (1993), 268/25 (18866-18874)
CODEN: JBCHA3 ISSN: 0021-9258

AU Garcia-Calvo M.; Leonard R.J.; Novick J.; Stevens S.P.; Schmalhofer W.;
Kaczorowski G.J.; Garcia M.L.
AN 1993:23273833 BIOTECHNO

L145 ANSWER 148 OF 199 MEDLINE on STN DUPLICATE 39

TI Cloning and sequencing of the gene encoding a 31-kilodalton antigen of
Haemophilus somnus.

SO Infection and immunity, (1993 Jul) Vol. 61, No. 7, pp. 2813-21.
Journal code: 0246127. ISSN: 0019-9567.

AU Won J; Griffith R W
AN 93293297 MEDLINE

L145 ANSWER 149 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

TI Large-scale production and purification of an Erwinia ananas ice
nucleation protein and evaluation of its ice nucleation activity;
**expression of recombinant ice nucleation
protein in Escherichia coli**

SO Biosci.Biotechnol.Biochem.; (1993) 57, 4, 603-06

CODEN: BBBIEJ

AU Watabe S; Abe K; Hirata A; Emori Y; Watanabe M; *Arai S
AN 1993-08191 BIOTECHDS

L145 ANSWER 150 OF 199 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation
on STN DUPLICATE 40

TI BIOSYNTHESIS OF BETA-(ISOXAZOLIN-5-ON-2-YL)-L-ALANINE BY **CYSTEINE**
SYNTHASE IN LATHYRUS-SATIVUS

SO PHYTOCHEMISTRY, (MAY 1993) Vol. 33, No. 1, pp. 93-98.
ISSN: 0031-9422.

AU IKEGAMI F (Reprint); ONGENA G; SAKAI R; ITAGAKI S; KOBORI M; ISHIKAWA T;
KUO Y H; LAMBEIN F; MURAKOSHI I

AN 1993:313418 SCISEARCH

L145 ANSWER 151 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

TI The effect of codon choice on expression and purification of bovine
placental lactogen;
optimization of cattle recombinant somatomammotropin production from
Escherichia coli by improved codon usage (conference
abstract)

SO J.Cell.Biochem.; (1993) Suppl.17A, 47
CODEN: JCEBD5

AU Curran D F; Kane J F; Violand B N; Staten N R; Duffin K L; Bogosian G

AN 1993-05552 BIOTECHDS

L145 ANSWER 152 OF 199 MEDLINE on STN DUPLICATE 41

TI Recombinant technology as an alternative to chemical peptide synthesis:
expression and characterization of HIV-1 Rev recombinant peptides.

SO Analytical biochemistry, (1993 Aug 15) Vol. 213, No. 1, pp. 40-8.
Journal code: 0370535. ISSN: 0003-2697.

AU Lepage P; Heckel C; Humbert S; Stahl S; Rautmann G

AN 94057379 MEDLINE

L145 ANSWER 153 OF 199 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation
on STN DUPLICATE 42

TI PURIFICATION AND CHARACTERIZATION OF 2 FORMS OF **CYSTEINE**
SYNTHASE FROM ALLIUM-TUBEROSUM

SO PHYTOCHEMISTRY, (JAN 1993) Vol. 32, No. 1, pp. 31-34.
ISSN: 0031-9422.

AU IKEGAMI F (Reprint); ITAGAKI S; MURAKOSHI I

AN 1993:60991 SCISEARCH

L145 ANSWER 154 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

TI Birch pollen allergen P14 for diagnosis and therapy of allergic diseases,
and recombinant production of the allergen

SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2

IN Valenta, Rudolf; Duchene, Michael; Pettenburger, Karin; Breitenbach,
Michael; Kraft, Dietrich; Rumpold, Helmut; Scheiner, Otto

AN 1992:569421 HCAPLUS

DN 117:169421

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9203551	A1	19920305	WO 1991-EP1513	19910809
	W: AU, CA, FI, JP, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	AT 9001685	A	19951115	AT 1990-1685	19900813
	AT 401180	B	19960725		
	CA 2067182	AA	19920214	CA 1991-2067182	19910809
	AU 9183901	A1	19920317	AU 1991-83901	19910809
	AU 659609	B2	19950525		
	EP 495064	A1	19920722	EP 1991-914581	19910809
	EP 495064	B1	20010711		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05502589	T2	19930513	JP 1991-513486	19910809

AT 203055	E	20010715	AT 1991-914581	19910809
NO 9201375	A	19920612	NO 1992-1375	19920408
NO 304189	B1	19981109		
FI 9201600	A	19920410	FI 1992-1600	19920410
FI 104983	B1	20000515		
US 5583046	A	19961210	US 1992-846992	19920606
US 5648242	A	19970715	US 1995-469555	19950606

L145 ANSWER 155 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
 TI cDNA cloning and molecular characterization of MSE55, a novel human serum constituent protein that displays bone marrow stromal/endothelial cell-specific expression
 SO Journal of Biological Chemistry (1992), 267(20), 13986-92
 CODEN: JBCHA3; ISSN: 0021-9258
 AU Bahou, Wadie F.; Campbell, Alan D.; Wicha, Max S.
 AN 1993:249987 HCAPLUS
 DN 118:249987

L145 ANSWER 156 OF 199 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN
 TI Proteolytic cleavage of the reovirus sigma 3 protein results in enhanced double-stranded RNA-binding activity: Identification of a repeated basic amino acid motif within the C-terminal binding region
 SO Journal of Virology, (1992), 66/9 (5347-5356)
 CODEN: JOVIAM ISSN: 0022-538X
 AU Miller J.E.; Samuel C.E.
 AN 1992:22262110 BIOTECHNO

L145 ANSWER 157 OF 199 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI BIOSYNTHESIS OF NEUROACTIVE AMINO-ACIDS BY **CYSTEINE SYNTHASES** IN LATHYRUS-LATIFOLIUS
 SO PHYTOCHEMISTRY, (JUN 1992) Vol. 31, No. 6, pp. 1991-1996.
 ISSN: 0031-9422.
 AU IKEGAMI F (Reprint); HORIUCHI S; KOBORI M; MORISHIGE I; MURAKOSHI I
 AN 1992:379915 SCISEARCH

L145 ANSWER 158 OF 199 MEDLINE on STN
 TI The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia.
 SO The Journal of biological chemistry, (1992 Jan 25) Vol. 267, No. 3, pp. 1962-8.
 Journal code: 2985121R. ISSN: 0021-9258.
 AU Horie Y; Fazio S; Westerlund J R; Weisgraber K H; Rall S C Jr
 AN 92112928 MEDLINE

L145 ANSWER 159 OF 199 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI PRODUCTION AND CHARACTERIZATION OF RECOMBINANT MOUSE NEUROTROPHIN-3
 SO EUROPEAN JOURNAL OF BIOCHEMISTRY, (1 MAR 1992) Vol. 204, No. 2, pp. 745-749.
 ISSN: 0014-2956.
 AU GOTZ R (Reprint); KOLBECK R; LOTTSPEICH F; BARDE Y A
 AN 1992:166892 SCISEARCH

L145 ANSWER 160 OF 199 MEDLINE on STN
 TI Purification and characterization of O-acetylserine (thiol) lyase from spinach chloroplasts.
 SO Archives of biochemistry and biophysics, (1992 Jun) Vol. 295, No. 2, pp. 379-90.
 Journal code: 0372430. ISSN: 0003-9861.
 AU Droux M; Martin J; Sajus P; Douce R
 AN 92264737 MEDLINE

L145 ANSWER 161 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

TI Purification and characterization of two forms of **cysteine synthase** from *Allium tuberosum*
 SO Phytochemistry (1992), 32(1), 31-4
 CODEN: PYTCAS; ISSN: 0031-9422
 AU Ikegami, Fumio; Itagaki, Satoshi; Murakoshi, Isamu
 AN 1993:163811 HCAPLUS
 DN 118:163811

L145 ANSWER 162 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI New isolates J1 and J7 of the hepatitis C virus;
 DNA sequence and protein sequence; DNA probe used in diagnosis;
recombinant protein antigen production in
Escherichia coli; recombinant vaccine
 AN 1991-06782 BIOTECHDS
 PI EP 419182 27 Mar 1991

L145 ANSWER 163 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Immunologic priming with **recombinant** hepatitis A virus capsid
proteins produced in Escherichia coli;
 cloning of the VP0, VP3 and VP1 capsid protein gene for potential
 application in subunit recombinant vaccine production
 SO J.Virol.; (1991) 65, 5, 2686-90
 CODEN: JOVIAM
 AU Powdrill T F; *Johnston J M
 AN 1991-06776 BIOTECHDS

L145 ANSWER 164 OF 199 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
 STN DUPLICATE 46
 TI **CYSTEINE SYNTHASE FROM A RED ALGA PORPHYRA-YEZOENSIS**
 PURIFICATION AND PROPERTIES.
 SO Japanese Journal of Phycology, (1991) Vol. 39, No. 1, pp. 7-14.
 CODEN: JJPHDP. ISSN: 0038-1578.
 AU FUJIMORI Y [Reprint author]; NAKAMURA K; TAMURA G
 AN 1991:276976 BIOSIS

L145 ANSWER 165 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 TI Biologic and biochemic properties of recombinant platelet factor-4
 demonstrate identity with the native protein;
 gene cloning and expression in *Escherichia coli*;
 purification and characterization
 SO Blood; (1990) 75, 6, 1290-95
 CODEN: BLOOAW
 AU Park K S; Rifat S; Eck H; Adachi K; Surrey S; *Poncz M
 AN 1990-07542 BIOTECHDS

L145 ANSWER 166 OF 199 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN
 TI Expression of guinea-pig liver transglutaminase cDNA in *Escherichia coli*. Amino-terminal N(α)-acetyl group is not essential for
 catalytic function of transglutaminase
 SO European Journal of Biochemistry, (1990), 187/3 (705-711)
 CODEN: EJBCAI ISSN: 0014-2956
 AU Ikura K.; Tsuchiya Y.; Sasaki R.; Chiba H.
 AN 1990:20074938 BIOTECHNO

L145 ANSWER 167 OF 199 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
 STN DUPLICATE 47
 TI ISOLATION OF SERINE ACETYLTRANSFERASE COMPLEXED WITH **CYSTEINE**
SYNTHASE FROM ALLIUM-TUBEROSUM.
 SO Agricultural and Biological Chemistry, (1990) Vol. 54, No. 3, pp. 649-656.
 CODEN: ABCHA6. ISSN: 0002-1369.
 AU NAKAMURA K [Reprint author]; TAMURA G
 AN 1990:336304 BIOSIS

L145 ANSWER 168 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
 TI Effect of protein overexpression on mistranslation in *Escherichia*

coli
SO Ribosome (1990), 546-58. Editor(s): Hill, Walter E. Publisher: Am. Soc. Microbiol., Washington, D. C.
CODEN: 57BFAW
AU Bogosian, Gregg; Violand, Bernard N.; Jung, Patricia E.; Kane, James F.
AN 1991:115888 HCAPLUS
DN 114:115888

L145 ANSWER 169 OF 199 MEDLINE on STN DUPLICATE 48
TI Isolation and characterization of recombinant eel growth hormone expressed in **Escherichia coli**.
SO Journal of chromatography, (1990 Aug 31) Vol. 515, pp. 483-94.
Journal code: 0427043. ISSN: 0021-9673.
AU Sugimoto S; Yamaguchi K; Yokoo Y
AN 91131740 MEDLINE

L145 ANSWER 170 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Cloning and prokaryote expression of a biologically active human placental aldose-reductase;
in **recombinant Escherichia coli**; PP9
protein sequence; potential application to
aldose-reductase-inhibitor **production**
SO DNA Cell Biol.; (1990) 9, 3, 149-57
AU Grundmann U; Bohn H; Obermeier R; Amann E
AN 1991-01082 BIOTECHDS

L145 ANSWER 171 OF 199 MEDLINE on STN DUPLICATE 49
TI Production of recombinant human tropoelastin: characterization and demonstration of immunologic and chemotactic activity.
SO Archives of biochemistry and biophysics, (1990 Jul) Vol. 280, No. 1, pp. 80-6.
Journal code: 0372430. ISSN: 0003-9861.
AU Indik Z; Abrams W R; Kucich U; Gibson C W; Mecham R P; Rosenbloom J
AN 90282506 MEDLINE

L145 ANSWER 172 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
TI Cloning and **expression** of synthetic human serum albumin gene and use of the **recombinant protein**.
SO Eur. Pat. Appl., 121 pp.
CODEN: EPXXDW
IN Aberg, Bertil; Simoncsits, Andras; Kalman, Miklos; Cserpan, Imre; Bajszar, Gyorgy
AN 1990:2041 HCAPLUS
DN 112:2041

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 308381	A1	19890322	EP 1988-850299	19880913
	EP 308381	B1	19960320		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	SE 8703539	A	19890315	SE 1987-3539	19870914
	SE 459586	B	19890717		
	WO 8902467	A1	19890323	WO 1988-SE470	19880913
	W: AU, BG, DK, FI, JP, KR, NO, RO, SU, US				
	AU 8824204	A1	19890417	AU 1988-24204	19880913
	AU 619495	B2	19920130		
	DD 282473	A5	19900912	DD 1988-319742	19880913
	JP 03501323	T2	19910328	JP 1988-507383	19880913
	JP 2865683	B2	19990308		
	AT 135740	E	19960415	AT 1988-850299	19880913
	CA 1340650	A1	19990713	CA 1988-577208	19880913
	IL 87748	A1	19930610	IL 1988-87748	19880914
	NO 9001177	A	19900418	NO 1990-1177	19900313
	DK 9000649	A	19900514	DK 1990-649	19900313
	DK 163937	B	19920421		
	DK 163937	C	19920914		

- L145 ANSWER 173 OF 199 MEDLINE on STN DUPLICATE 50
TI Characterization of **recombinant** thioesterase and acyl carrier **protein** domains of chicken fatty acid synthase **expressed** in *Escherichia coli*.
SO The Journal of biological chemistry, (1989 Oct 25) Vol. 264, No. 30, pp. 18195-201.
Journal code: 2985121R. ISSN: 0021-9258.
AU Pazirandeh M; Chirala S S; Huang W Y; Wakil S J
AN 90036899 MEDLINE
- L145 ANSWER 174 OF 199 LIFESCI COPYRIGHT 2006 CSA on STN DUPLICATE 51
TI Purification and properties of beta -cyano-L-alanine synthase from *Vicia angustifolia* .
SO PHYTOCHEMISTRY., (1989) vol. 28, no. 9, pp. 2285-2291.
AU Ikegami, F.; Takayama, K.; Kurihara, T.; Horiuchi, S.; Tajima, C.; Shirai, R.; Murakoshi, I.
AN 89:85682 LIFESCI
- L145 ANSWER 175 OF 199 MEDLINE on STN
TI Synthesis of glia-derived nexin in yeast.
SO Gene, (1989 Dec 28) Vol. 85, No. 2, pp. 453-9.
Journal code: 7706761. ISSN: 0378-1119.
AU Sommer J; Meyhack B; Rovelli G; Buergi R; Monard D
AN 90185220 MEDLINE
- L145 ANSWER 176 OF 199 MEDLINE on STN DUPLICATE 52
TI Recombinant anaerobic maize aldolase: overexpression, characterization, and metabolic implications.
SO Archives of biochemistry and biophysics, (1989 Aug 1) Vol. 272, No. 2, pp. 281-9.
Journal code: 0372430. ISSN: 0003-9861.
AU Berthiaume L; Beaudry D; Lazure C; Tolan D R; Sygusch J
AN 89321538 MEDLINE
- L145 ANSWER 177 OF 199 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN
TI Isolation of recombinant partial gag gene product p18 (HIV-1(Bru) from *Escherichia coli*
SO Journal of Chromatography, (1989), 476/- (99-112)
CODEN: JOCRAM ISSN: 0021-9673
AU Kolbe H.V.J.; Jaeger F.; Lepage P.; Roitsch C.; Lacaud G.; Kieny M.-P.; Sabatie J.; Brown S.W.; Lecocq J.-P.; Girard M.
AN 1989:19193616 BIOTECHNO
- L145 ANSWER 178 OF 199 MEDLINE on STN DUPLICATE 53
TI Isolation and characterization of biologically active murine interleukin-1 alpha derived from expression of a synthetic gene in *Escherichia coli*.
SO Biochimica et biophysica acta, (1989 Sep 14) Vol. 998, No. 1, pp. 32-42.
Journal code: 0217513. ISSN: 0006-3002.
AU Daumy G O; Merenda J M; McColl A S; Andrews G C; Franke A E; Geoghegan K F; Otterness I G
AN 90001293 MEDLINE
- L145 ANSWER 179 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI **Production of recombinant protein** with amino acid extension and signal sequence; potential application in interleukin-1, somatomedin-C, insulin and somatotropin production
AN 1989-03729 BIOTECHDS
PI WO 8810299 29 Dec 1988
- L145 ANSWER 180 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
TI **Recombinant protein production** in

microorganisms in form of fusion protein with aminoglycoside
3-phosphotransferase II

SO Eur. Pat. Appl., 32 pp.

CODEN: EPXXDW

IN Teraoka, Hiroshi; Shin, Masaru; Ohara, Osamu; Kikuchi, Norihisa

AN 1988:433229 HCAPLUS

DN 109:33229

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 264118	A2	19880420	EP 1987-115016	19871014
	EP 264118	A3	19881214		
	EP 264118	B1	19930804		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 63267289	A2	19881104	JP 1987-253437	19871006
	AU 8779765	A1	19880421	AU 1987-79765	19871014
	AU 603145	B2	19901108		
	AT 92528	E	19930815	AT 1987-115016	19871014
	ES 2059340	T3	19941116	ES 1987-115016	19871014
	CA 1339736	A1	19980317	CA 1987-549072	19871014

L145 ANSWER 181 OF 199 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI PURIFICATION AND PROPERTIES OF BETA CYANO-L-ALANINE SYNTHASE FROM
LATHYRUS-LATIFOLIUS.

SO Phytochemistry (Oxford), (1988) Vol. 27, No. 11, pp. 3385-3390.

CODEN: PYTCAS. ISSN: 0031-9422.

AU IKEGAMI F [Reprint author]; TAKAYAMA K; MURAKOSHI I

AN 1989:98597 BIOSIS

L145 ANSWER 182 OF 199 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN DUPLICATE 54

TI PURIFICATION AND CHARACTERIZATION OF **CYSTEINE SYNTHASE**
FROM BRASSICA-JUNCEA.

SO Phytochemistry (Oxford), (1988) Vol. 27, No. 11, pp. 3379-3384.

CODEN: PYTCAS. ISSN: 0031-9422.

AU IKEGAMI F [Reprint author]; KANEKO M; KOBORI M; MURAKOSHI I

AN 1989:98596 BIOSIS

L145 ANSWER 183 OF 199 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN DUPLICATE 55

TI PURIFICATION AND PROPERTIES OF BETA CYANO-L-ALANINE SYNTHASE FROM
SPINACIA-OLERACEA.

SO Phytochemistry (Oxford), (1988) Vol. 27, No. 7, pp. 2011-2016.

CODEN: PYTCAS. ISSN: 0031-9422.

AU IKEGAMI F [Reprint author]; TAKAYAMA K; TAJIMA C; MURAKOSHI I

AN 1988:401493 BIOSIS

L145 ANSWER 184 OF 199 LIFESCI COPYRIGHT 2006 CSA on STN DUPLICATE 56

TI Purification and characterization of **cysteine synthases**
from Citrullus vulgaris .

SO PHYTOCHEMISTRY., (1988) vol. 27, no. 3, pp. 697-701.

AU Ikegami, F.; Kaneko, M.; Kamiyama, H.; Murakoshi, I.

AN 88:75168 LIFESCI

L145 ANSWER 185 OF 199 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN DUPLICATE 57

TI PURIFICATION AND SOME PROPERTIES OF PLANT SERINE ACETYLTRANSFERASE.

SO Plant and Cell Physiology, (1988) Vol. 29, No. 4, pp. 689-694.

CODEN: PCPHA5. ISSN: 0032-0781.

AU NAKAMURA K [Reprint author]; HAYAMA A; MASADA M; FUKUSHIMA K; TAMURA G

AN 1988:379359 BIOSIS

L145 ANSWER 186 OF 199 MEDLINE on STN DUPLICATE 58

TI Sugar transport by the bacterial phosphotransferase system. Molecular
cloning and structural analysis of the Escherichia coli ptsH, ptsI, and

crr genes.

SO The Journal of biological chemistry, (1987 Nov 25) Vol. 262, No. 33, pp. 16241-53.
Journal code: 2985121R. ISSN: 0021-9258.

AU Saffen D W; Presper K A; Doering T L; Roseman S
AN 88058992 MEDLINE

L145 ANSWER 187 OF 199 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 59

TI DIFFERENCE BETWEEN URACILYLALANINE SYNTHASES AND **CYSTEINE SYNTHASES** IN PISUM-SATIVUM.

SO Phytochemistry (Oxford), (1987) Vol. 26, No. 10, pp. 2699-2704.
CODEN: PYTCAS. ISSN: 0031-9422.

AU IKEGAMI F [Reprint author]; KANEKO M; LAMBEIN F; JUO Y-H; MURAKOSHI I
AN 1988:32741 BIOSIS

L145 ANSWER 188 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

TI Purification strategy for recombinant DNA malaria antigens expressed in *E. coli*;
for use in vaccine (conference abstract)

SO Fed.Proc.Fed.Am.Soc.Exp.Biol.; (1987) 46, 6, 2275
CODEN: FEPR7

AU Wasserman G F; Inacker R; Silverman C C; Rosenbloom J; Sitrin R; DePhillips P
AN 1987-08364 BIOTECHDS

L145 ANSWER 189 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

TI The construction, cloning and expression of synthetic genes coding for completely new, nutritionally rich, artificial proteins;
artificial protein preparation; artificial gene cloning and expression in *Escherichia coli* (conference abstract)

SO Protein Engineering 87; (1987) 44

AU Biernat J; Hasselman J; Hofer B; Kennedy N; Koester H
AN 1989-05816 BIOTECHDS

L145 ANSWER 190 OF 199 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 60

TI PURIFICATION AND PROPERTIES OF **CYSTEINE SYNTHASE** FROM SPINACIA-OLERACEA.

SO Phytochemistry (Oxford), (1985) Vol. 24, No. 9, pp. 1907-1912.
CODEN: PYTCAS. ISSN: 0031-9422.

AU MURAKOSHI I [Reprint author]; IKEGAMI F; KANEKO M
AN 1986:97541 BIOSIS

L145 ANSWER 191 OF 199 MEDLINE on STN DUPLICATE 61

TI Location on the *Escherichia coli* genome of a gene specifying O-acetylserine (thiol)-lyase.

SO Journal of general microbiology, (1984 Mar) Vol. 130, No. 3, pp. 673-85.
Journal code: 0375371. ISSN: 0022-1287.

AU Boronat A; Britton P; Jones-Mortimer M C; Kornberg H L; Lee L G; Murfitt D; Parra F
AN 84214945 MEDLINE

L145 ANSWER 192 OF 199 MEDLINE on STN

TI A new class of mutants of the *cysB* regulatory gene for cysteine biosynthesis in *Salmonella typhimurium*.

SO Journal of general microbiology, (1982 Aug) Vol. 128, No. 8, pp. 1785-90.
Journal code: 0375371. ISSN: 0022-1287.

AU Wiater A; Filutowicz M; Hulanicka D
AN 83058678 MEDLINE

L145 ANSWER 193 OF 199 MEDLINE on STN DUPLICATE 62

TI Cysteine and homocysteine synthesis in *Saccharomycopsis lipolytica*; identification and characterization of two **cysteine synthases**.

SO Acta biochimica Polonica, (1982) Vol. 29, No. 1-2, pp. 81-93.
Journal code: 14520300R. ISSN: 0001-527X.
AU Morzycka E; Paszewski A
AN 83096142 MEDLINE

L145 ANSWER 194 OF 199 MEDLINE on STN
TI Overall mechanism and rate equation for O-acetylserine sulphydrylase.
SO The Journal of biological chemistry, (1977 May 25) Vol. 252, No. 10, pp. 3459.
Journal code: 2985121R. ISSN: 0021-9258.
AU Cook P F; Wedding R T
AN 77187827 MEDLINE

L145 ANSWER 195 OF 199 MEDLINE on STN
TI O-Acetylserine and O-acetylhomoserine sulphydrylase of yeast. Subunit structure.
SO Journal of biochemistry, (1976 Oct) Vol. 80, No. 4, pp. 787-97.
Journal code: 0376600. ISSN: 0021-924X.
AU Yamagata S
AN 77093759 MEDLINE

L145 ANSWER 196 OF 199 MEDLINE on STN DUPLICATE 63
TI Studies on the mechanism of inhibition of Salmonella typhimurium by 1,2,4-triazole.
SO The Journal of biological chemistry, (1975 Sep 25) Vol. 250, No. 18, pp. 7324-31.
Journal code: 2985121R. ISSN: 0021-9258.
AU Kredich N M; Foote L J; Hulanicka M D
AN 76024938 MEDLINE

L145 ANSWER 197 OF 199 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Some physical and chemical properties of serinesulphydrase from chicken liver (Russian).
SO Biokhimiya, (1975) Vol. 40, No. 3, pp. 505-512. .
CODEN: BIOHAO
AU Yefremova L.L.; Goryachenkova E.V.
AN 76099969 EMBASE

L145 ANSWER 198 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
TI Specificity and some other properties of liver serine sulphydrase. Evidence for its identity with cystathione β -synthase
SO Biochimica et Biophysica Acta, Enzymology (1971), 242(1), 247-60
CODEN: BBEZAD; ISSN: 0924-1086
AU Braunshtein, A. E.; Goryachenkova, E. V.; Tolosa, E. A.; Willhardt, I. H.; Efremova, L. L.
AN 1971:494942 HCAPLUS
DN 75:94942

L145 ANSWER 199 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN
TI Biosynthesis of cysteine from serine and hydrogen sulfide
SO Biochemische Zeitschrift (1957), 328, 591-4
CODEN: BIZEA2; ISSN: 0366-0753
AU Schlossmann, Klaus; Lynen, Feodor
AN 1957:62619 HCAPLUS
DN 51:62619
OREF 51:11414f-g

=>
=> d ab 29,64,68-70,81,94,101,105-107,110,114,119,127,128,132,136,137,149

L145 ANSWER 29 OF 199 MEDLINE on STN DUPLICATE 1
AB Variations in proteome **profiles** of Escherichia coli in response to the overproduction of human leptin, a **serine-**

rich (11.6% of total amino acids) protein, were examined by two-dimensional gel electrophoresis. The levels of heat shock proteins increased, while those of protein elongation factors, 30S ribosomal protein, and some enzymes involved in amino acid biosynthesis decreased, after leptin overproduction. Most notably, the levels of enzymes involved in the biosynthesis of **serine** family amino acids significantly decreased. Based on this information, we designed a strategy to enhance the leptin productivity by manipulating the **cysK** gene, encoding **cysteine synthase A**. By **coexpression** of the **cysK** gene, we were able to increase the cell growth rate by approximately twofold. Also, the specific leptin productivity could be increased by fourfold. In addition, we found that **cysK coexpression** can improve the production of another **serine-rich** protein, interleukin-12 beta chain, suggesting that this strategy may be useful for the production of other **serine-rich** proteins as well. The approach taken in this study should be useful in designing a strategy for improving **recombinant protein production**.

L145 ANSWER 64 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

AB Isolated nucleic acid mols., designated metabolic pathway protein (MP) nucleic acid mols., which encode novel MP proteins from *Phycomitrella patens* are described. The cDNA sequences and the encoded amino acid sequences of a number of MP enzymes and proteins are disclosed. The invention also provides antisense nucleic acid mols., **recombinant expression** vectors containing MP **protein** nucleic acid mols., and host cells into which the **expression** vectors have been introduced. The invention still further provides isolated MP proteins, mutated MP proteins, fusion proteins, antigenic peptides and methods for the improvement of production of a desired compound from transformed cells, organisms or plants based on genetic engineering of MP protein genes in these organisms.

L145 ANSWER 68 OF 199 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AB The 1x myc-tagged cDNA encoding for human CIS2 protein was subcloned into a pET-29a+ vector in order to express and produce a recombinant S-peptide tagged and 1x myc-tagged protein in *Escherichia coli* BL21(DE3). The constitutively expressed protein was isolated from inclusion bodies by a simple solubilization-renaturation procedure and purified by anion-exchange chromatography on Q-Sepharose. The recombinant form was found to be pure and monomeric as judged by both SDS-PAGE and gel-filtration chromatography and its biological activity was proven by its ability to bind to the tyrosine-phosphorylated cytosolic fragment of human growth hormone receptor fused to glutathione-S-transferase. Recombinant CIS2 was compared by biochemical, immunological, and molecular methods to the CIS2 protein expressed in eukaryotic cells. This report describes the first substantial production of biologically active recombinant human CIS2.

L145 ANSWER 69 OF 199 LIFESCI COPYRIGHT 2006 CSA on STN

AB Recombinant human CRP (rhCRP) was secreted into culture supernatant of *Escherichia coli* by co-expressing *kil* gene that has a function to secrete colicin E1 outside the cell. Highly purified 5 g rhCRP was produced from 180 L culture supernatant by affinity chromatography. The purified rhCRP was indistinguishable from the native one with respect to Ca super(2+) -dependent binding ability to phosphorylcholine, electrophoretic behavior, N-terminal amino acid analysis, and immunochemical properties. The molecular weight of rhCRP monomer was determined to be 23059.7 Da by TOF/MS analysis. These results indicate that rhCRP has the same protein structure as native one and that rhCRP has the potential as a reference material and/or calibrator of high-sensitivity CRP assay to predict the risk of cardiovascular disease. [copy] 2002 Elsevier Science (USA)

L145 ANSWER 70 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

AB A sporulating culture of *Bacillus thuringiensis* subsp. *kenyae* strain HD549 is toxic to larvae of lepidopteran insect species such as *Spodoptera litura*, *Helicoverpa armigera* and *Phthorimaea operculella*, and a dipteran insect, *Culex fatigans*. A 1.9-kb DNA fragment, PCR-amplified from HD549 using cryll-gene-specific primers, was cloned and expressed in *E. coli*. The **recombinant protein** produced 92% mortality in first-instar larvae of *Spodoptera litura* and 86% inhibition of adult emergence in *Phthorimaea operculella*, but showed very low toxicity against *Helicoverpa armigera*, and lower mortality against third-instar larvae of dipteran insects *Culex fatigans*, *Anopheles stephensi* and *Aedes aegypti*. The sequence of the cloned crystal protein gene showed almost complete homol. with a mosquitocidal toxin gene from *Bacillus thuringiensis* var. *kurstaki*, with only five mutations scattered in different regions. Amino acid alignment with different insecticidal crystal proteins using the MUTALIN program suggested presence of the conserved block 3 region in the sequence of this protein. A mutation in codon 409 of this gene that changes a highly conserved phenylalanine residue to serine lies in this block.

L145 ANSWER 81 OF 199 BIOTECHNO COPYRIGHT 2006 Elsevier Science B.V. on STN

AB β -(Pyrazol-1-yl)-L-alanine (β -PA) was produced from L-serine and pyrazol using recombinant *Escherichia coli* cells expressing serine acetyltransferase and O-acetylserine sulphydrylase-A. The amount of β -PA increased with increasing L-serine concentrations up to 600 mM at 50 mM pyrazol while 100 mM pyrazol gave the highest β -PA production with 50 mM L-serine. Under the **optimized** conditions, β -PA accumulated in the broth at approximately 140 mM with a conversion of 90% with respect to the added amount of pyrazol.

L145 ANSWER 94 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

AB HPLC6 is the major component of liver-type antifreeze polypeptides (AFPs) from the winter flounder, *Pleuronectes americanus*. To facilitate mutagenesis studies of this protein, a gene encoding the 37-amino acid mature polypeptide was chemical synthesized and cloned into the Tac cassette immediately after the bacterial ompA leader sequence for direct excretion of the AFP into the culture medium. *Escherichia coli* transformant with the construct placiQpar8AF was cultured in M9 medium. The recombinant AFP (rAFP) was detected by a competitive ELISA. After IPTG induction, a biol. active rAFP was expressed. The majority of the rAFP was excreted into the culture medium with only trace amts. trapped in the periplasmic space and cytoplasm. After 18 h of induction, the accumulated rAFP in the culture medium amounted to about 16 mg/L. The excreted AFP was purified from the culture medium by a single-step reverse-phase HPLC. Mass spectrometric and **amino acid composition** analyses confirmed the identity of the purified product. The rAFP, which lacked amidation at the C-terminal, was about 70% active when compared to the amidated wild-type protein, thus confirming the importance of C-terminal cap structure in protein stability and function. (c) 2000 Academic Press.

L145 ANSWER 101 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

AB The consensus repeat sequence found in the dragline silk from the spider, *Nephila clavipes*, was redesigned to incorporate a redox trigger flanking the β -sheet-forming polyalanine sequences. The methionine redox trigger, in the oxidized state, was incorporated to prevent the formation of the β -sheets; in the reduced state it would not result in steric limitations to β -sheet formation. A synthetic gene incorporating the trigger was constructed, cloned, and expressed in *Escherichia coli*. The purified protein, .apprx.25 kDa, contained the expected **amino acid composition** and migration behavior on SDS-PAGE. The recombinant protein was analyzed by x-ray diffraction, TEM, electron diffraction, and CD in both oxidized and reduced states. Based on the results, the incorporation of a redox trigger appears to be a powerful exptl. strategy to explore the self-assembly of fibrous proteins

such as silks.

L145 ANSWER 105 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

AB The combination of 2-D PAGE, computer image anal., and several protein identification techniques allowed the Escherichia coli SWISS-2DPAGE database to be established. This is part of the ExpASY mol. biol. server accessible through the WWW at the URL address <http://www.expasy.ch/ch2d/ch2d-top.html>. The authors report recent progress in the development of the E. coli SWISS-2DPAGE database. Proteins were separated with immobilized pH gradients in the 1st dimension and Na dodecyl sulfate-polyacrylamide gel electrophoresis in the 2nd dimension. To increase the resolution of the separation and thus the number of identified proteins, a variety of wide and narrow range immobilized pH gradients were used in the 1st dimension. Micropreparative gels were electroblotted onto polyvinylidene difluoride membranes and spots were visualized by amido black staining. Protein identification techniques such as **amino acid composition** anal., gel comparison and microsequencing were used, as well as a recently described Edman sequence tag approach. Some of the above identification techniques were coupled with database searching tools. Currently 231 polypeptides are identified on the E. coli SWISS-2DPAGE map: 64 were identified by N-terminal microsequencing, 39 by **amino acid composition**, and 82 by sequence tag. Of 153 proteins putatively identified by gel comparison, 65 were confirmed. Many proteins were identified using more than 1 technique. Faster progress in the E. coli proteome project will now be possible with advances in biochem. methodol. and with the completion of the entire E. coli genome.

L145 ANSWER 106 OF 199 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 16

AB The psoriasis-associated fatty acid binding protein (PA-FABP, also known as FABP5) is a novel keratinocyte protein that is highly up-regulated in psoriatic plaques (P. Madsen, H.H. Rasmussen, H. Leffers, B. Honore and J.E. Celis, J. Invest. Dermatol. 1992, 99, 299-305). Here we have expressed PA-FABP in Escherichia coli as a fusion protein containing an NH2-terminal hexa-His tag followed by a factor Xa cleavage site. The **recombinant protein** was **expressed** at a level of about 30% of the soluble proteins and was purified to homogeneity using a simple two-step protocol consisting of affinity chromatography on Ni²⁺-nitrilotriacetic acid agarose followed by gel filtration. The recombinant protein was then digested with factor Xa and characterized by two-dimensional gel electrophoresis. The ability of PA-FABP to bind saturated fatty acids ranging from 6 to 16 carbons was determined directly by dialysis and compared to human serum albumin (HSA). The results showed that PA-FABP binds multiple molecules of the fatty acids hexanoate (C(6:)), octanoate (C(8:0)), decanoate (C(10:0)) and laurate (C(12:0)), all with a K₁ of about 10⁴ M⁻¹, and myristate (C(14:0)) with a K₁ of 4.4 X 10⁵ M⁻¹. Palmitate (C(16:)) also bound strongly with multiple molecules. Due to the very low solubility of palmitate its affinity to PA-FABP was measured relatively to HSA and found to be 8.1 times lower. At ligand/protein ratios below 1, all fatty acids bound to PA-FABP with about one to three orders of magnitude lower affinity than to HSA. The difference in the fatty acid binding properties of the two proteins may reflect differences in their three-dimensional structures, which in the case of PA-FABP consists mainly of β -sheets while HSA contains predominantly α -helices.

L145 ANSWER 107 OF 199 LIFESCI COPYRIGHT 2006 CSA on STN

AB Coexpression of di- α -globin and β -globin in Escherichia coli in the presence of exogenous heme yielded high levels of soluble, functional recombinant human hemoglobin (rHb1.1). High-level **expression** of rHb1.1 provides a good model for measuring mistranslation in **heterologous proteins**. rHb1.1 does not contain isoleucine; therefore, any isoleucine present could be attributed to mistranslation, most likely mistranslation of one or more of

the 200 codons that differ from an isoleucine codon by 1 bp. Sensitive amino acid analysis of highly purified rHb1.1 typically revealed less than or equal to 0.2 mol of isoleucine per mol of hemoglobin. This corresponds to a translation error rate of less than or equal to 0.001, which is not different from typical translation error rates found for *E. coli* proteins. Two different expression systems that resulted in accumulation of globin proteins to levels equivalent to similar to 20% of the level of *E. coli* soluble proteins also resulted in equivalent translational fidelity.

L145 ANSWER 110 OF 199 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation
on STN DUPLICATE 19

AB The amplified **expression** of a **recombinant protein** is known to lead to an intracellular depletion of specific amino acid pools which in turn may affect the production of the desired protein. In order to counteract and overcome such a situation during the fermentation of the recombinant *Escherichia coli* (PMSG27) containing the glucose isomerase (GI) gene from *Streptomyces* sp. NCIM 2730, the effect of addition of different amino acids on the specific activity of GI was studied. The **amino acid composition** of GI from *Streptomyces* sp. NCIM 2730 reveals predominantly aspartic acid, glutamic acid, and glycine; therefore, in the present paper; the effect of coordinated addition of the assorted combinations of these three amino acids on the synthesis of recombinant GI was studied. The results were analyzed using a 2(3) factorial design. The following conclusions were derived from the analysis of two-factor interactions of the three amino acids: (i) The interaction between the aspartic and glutamic acid is independent of aspartic acid concentration but is affected by the increasing concentrations of glutamic acid, (ii) The effect of aspartic acid concentration is more than that of glycine, and (iii) During the interaction of glutamic acid and glycine, the effect of glutamic acid is more prominent than that of glycine. The three-factor interaction analyses reveal that the effect of the three amino acids is in the order aspartic acid > glutamic acid > glycine. (C) 1998 Elsevier Science Inc.

L145 ANSWER 114 OF 199 LIFESCI COPYRIGHT 2006 CSA on STN

AB Isolation of the **recombinant protein** from a genetically engineered *Escherichia coli* 1854 **producer** for further chemical enzymatic transformation into human insulin through proinsulin was studied. Under optimal conditions, the recombinant protein formation was more than 35% of the total cell proteins. Structures of the polypeptides obtained and purified chromatographically were confirmed by amino acid analysis. Human proinsulin was derived from the recombinant protein isolated.

L145 ANSWER 119 OF 199 MEDLINE on STN DUPLICATE 24

AB A partial cDNA clone, from the 3' end of the dragline silk gene was isolated from *Nephila clavipes* major ampullate glands. This clone contains a 1.7-kb insert, consisting of a repetitive coding region of 1.4-kb and a 0.3-kb nonrepetitive coding region; 1.5-kb of the 1.7-kb fragment was cloned into *Escherichia coli* and a 43-kDa **recombinant silk protein** was **expressed**. Characterization of the purified protein by Western blot, **amino acid composition** analysis, and matrix-assisted laser desorption ionization/time-of-flight mass spectrometry confirms it to be spider dragline silk.

L145 ANSWER 127 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

AB Previous research has shown that overexpression of recombinant proteins places a metabolic burden on the host cell. Anal. shows that **recombinant proteins expressed** in *Escherichia coli* at less than 10% of total protein have an average **amino acid composition** which is rich in amino acids from the aromatic and **serine** biosynthetic families. A neg. correlation is observed

between expression level and aromatic amino acid and cysteine content relative to the host. We hypothesize that when an amino acid is present in a recombinant protein at levels significantly higher than present in host cellular protein, the amino acid becomes a limiting factor in expression level. Results will be presented which suggest that 1) the **amino acid composition of a recombinant protein** can affect its **expression level**, and 2) the metabolic burden imposed by **amino acid compn** . can be alleviated by supplementing the cell with required precursors, leading to significant increases in **recombinant protein expression**.

L145 ANSWER 128 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

AB Gilthead seabream (*S. aurata*) insulin-like growth factor-I (gsIGF-I) cDNA coding for the mature protein was cloned in a pGEM-3Z vector, and then transferred into prokaryotic expression vector pET-11a and expressed in *E. coli* BL21(DE3) cells upon induction with iso-Pr thiogalactoside. The expressed protein contained within the inclusion-body pellet was solubilized in 4.5M urea, refolded for 24 h at pH 11.3 in the presence of catalytic amts. of cysteine, and purified to >98% purity, as a monomeric methionyl-gsIGF-I. **Amino acid composition** and N-terminal sequence confirmed the identity to be the predicted protein. Binding assays of the ¹²⁵I-gsIGF-I to gilthead seabream or carp (*Cyprinus carpio*) sera resulted in high specific binding, indicating the existence of ≥ 1 IGF-binding proteins. In binding expts. to crude gilthead seabream brain homogenate, using human (h) IGF-I, as a ligand, the resp. IC50 value of hIGF-I was .apprx.4-fold lower than that of gsIGF-I. Recombinant gsIGF-I exhibited mitogenic activity in a mouse mammary gland-derived MME-L1 cell line which was .apprx.200-fold lower than that of hIGF-I. Binding expts. to intact MME-L1 cells suggests that this difference most likely results from a correspondingly lower affinity for IGF-I receptor in these cells. In contrast, the activities of gsIGF-I and hIGF-I measured by ³⁵S uptake by gill arches from the goldfish (*Carassius auratus*) were identical, indicating that the recombinant gsIGF-I is biol. active.

L145 ANSWER 132 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

AB Previous research has shown that overexpression of recombinant proteins places a metabolic burden on the host cell. Analysis shows that **recombinant proteins expressed** in *Escherichia coli* at less than 10% of total protein have an average **amino acid composition** which is rich in amino acids from the aromatic and **serine** biosynthetic families. A negative correlation was observed between expression level and aromatic amino acid and cysteine content relative to the host. It was hypothesized that when an amino acid is present in a recombinant protein at levels significantly higher than present in host cellular protein, the amino acid becomes a limiting factor in expression level. Results were presented which suggest that the **amino acid composition of a recombinant protein** can affect its **expression level** and the metabolic burden imposed by **amino acid composition** can be alleviated by supplementing the cell with required precursors, leading to significant increases in **recombinant protein production** . (0 ref)

L145 ANSWER 136 OF 199 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN

AB Fed-batch culture with controlled L-**amino acid composition** was performed to improve production of a recombinant gene product in *Bacillus brevis*. The maximum recombinant protein (alpha-amylase) level and specific activity increased from 5.14 kU/mL and 0.77 kU/mg dry cell in conventional fed-batch culture to 12.01 kU/mL and 2.64 kU/mg dry cell, respectively, when L-amino acid concentration was controlled at 5 mM using an asparagine (Asn)- and isoleucine

(Ile)-enriched nitrogen source. The L-amino acid concentration in the culture was monitored by an automatic biotech analyzer and controlled at 2-20 mM using a mixture of polypeptone and yeast extract. Although L-amino acid concentrations were controlled at low levels, the alpha-amylase activity increased only 1.3 times compared to an uncontrolled batch culture; accumulation of ammonium ion was not reduced. When L-amino acid was controlled at the high level, more cell mass and less recombinant gene product were produced than in those with low control level. To overcome ammonium ion inhibition, the specific amino acids Asn and lie were substituted to improve the production of gene product. Addition of these amino acids to a flask culture led to an improvement in the enzyme production level and specific activity to 2.9 and 5.1 times, respectively, as high as that without them. Both the control of amino acids at low concentrations and the enrichment of Asn and lie were effective for the improvement of **recombinant protein production** from recombinant *B. brevis* cells. (C) 1996 John Wiley & Sons, Inc.

L145 ANSWER 137 OF 199 HCAPLUS COPYRIGHT 2006 ACS on STN

AB **Heterologous proteins** may be **expressed** in bacteria, where protein engineering techniques can be used to alter the amino acid sequence. As the **amino acid compn** . of the mol. shifts, it is sometimes possible to identify proteins with augmented properties or to identify domains crucial for biol. function. We have developed **expression** systems that make it possible to **produce recombinant proteins** at high yield from *E. coli* where partitioning of the **product** into a cellular compartment can complement a purification strategy. We have now developed an expression system for the production of small peptides by recombinant means at high yield, including when the peptide is a component of a larger fusion protein. Data will be presented on the recombinant production and purification of antifungal peptides from bacteria. In addition, we linked antifungal peptides to a protein carrier to initiate peptide engineering studies with these recombinant fusion proteins. As with recombinant proteins, peptide fusions can be used to characterize and evolve the functional peptide unit.

L145 ANSWER 149 OF 199 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

AB The ice nucleation-active protein of *Erwinia ananas* IN-10 (inaA protein) was over-expressed as inclusion bodies in *Escherichia coli* YA21 harboring plasmid pINA6S13. The inaA protein was purified from inclusion bodies by repeated solubilization with Triton X-100 to obtain a protein preparation free from sugar and lipid. The yield was 15.3 mg of inaA protein from 60 mg of bacterial cells on a dry weight basis. The N-terminal amino acid sequence of the purified inaA protein was Met-Lys-Glu-Asp-Lys-Val-Leu-Ile-Leu, which agreed exactly with that predicted from the inaA gene. The **amino acid composition** corresponded approximately with that predicted from the sequence of the inaA gene. The small deviation from the predicted value may have been a result of the very high mol.weight, 130,000, of the inaA protein. The purified protein showed ice nucleation activity, indicating that the inaA protein per se was able to act as an ice nucleus. The study establishes a simplified and enlarged system for the production of pure inaA protein. The protein could be used for the mild freeze-concentration of foods and other materials sensitive to deep-freezing. (20 ref)

=> s quorum sens?

FILE 'MEDLINE'

1182 QUORUM

925674 SENS?

L146 1101 QUORUM SENS?

(QUORUM(W) SENS?)

```

FILE 'SCISEARCH'
    1622 QUORUM
    971595 SENS?
L147    1335 QUORUM SENS?
        (QUORUM(W) SENS?)

FILE 'LIFESCI'
    860 "QUORUM"
    230521 SENS?
L148    847 QUORUM SENS?
        ("QUORUM" (W) SENS?)

FILE 'BIOTECHDS'
    68 QUORUM
    28884 SENS?
L149    64 QUORUM SENS?
        (QUORUM(W) SENS?)

FILE 'BIOSIS'
    1427 QUORUM
    1569150 SENS?
L150    1399 QUORUM SENS?
        (QUORUM(W) SENS?)

FILE 'EMBASE'
    1002 "QUORUM"
    811390 SENS?
L151    968 QUORUM SENS?
        ("QUORUM" (W) SENS?)

FILE 'HCAPLUS'
    1443 QUORUM
    1306103 SENS?
L152    1415 QUORUM SENS?
        (QUORUM(W) SENS?)

FILE 'NTIS'
    33 QUORUM
    130207 SENS?
L153    9 QUORUM SENS?
        (QUORUM(W) SENS?)

FILE 'ESBIOBASE'
    1041 QUORUM
    356142 SENS?
L154    1016 QUORUM SENS?
        (QUORUM(W) SENS?)

FILE 'BIOTECHNO'
    540 QUORUM
    182320 SENS?
L155    530 QUORUM SENS?
        (QUORUM(W) SENS?)

FILE 'WPIDS'
    110 QUORUM
    920589 SENS?
L156    40 QUORUM SENS?
        (QUORUM(W) SENS?)

TOTAL FOR ALL FILES
L157    8724 QUORUM SENS?

=> s l157 and l12
FILE 'MEDLINE'

```

L158 2 L146 AND L1

FILE 'SCISEARCH'

L159 2 L147 AND L2

FILE 'LIFESCI'

L160 2 L148 AND L3

FILE 'BIOTECHDS'

L161 0 L149 AND L4

FILE 'BIOSIS'

L162 4 L150 AND L5

FILE 'EMBASE'

L163 2 L151 AND L6

FILE 'HCAPLUS'

L164 3 L152 AND L7

FILE 'NTIS'

L165 0 L153 AND L8

FILE 'ESBIOBASE'

L166 2 L154 AND L9

FILE 'BIOTECHNO'

L167 1 L155 AND L10

FILE 'WPIDS'

L168 1 L156 AND L11

TOTAL FOR ALL FILES

L169 19 L157 AND L12

=> dup rem l169

PROCESSING COMPLETED FOR L169

L170 5 DUP REM L169 (14 DUPLICATES REMOVED)

=> d tot

L170 ANSWER 1 OF 5 MEDLINE on STN DUPLICATE 1
TI Differential gene expression for investigation of Escherichia coli biofilm inhibition by plant extract ursolic acid.
SO Applied and environmental microbiology, (2005 Jul) Vol. 71, No. 7, pp. 4022-34.
Journal code: 7605801. ISSN: 0099-2240.
AU Ren Dacheng; Zuo Rongjun; Gonzalez Barrios Andres F; Bedzyk Laura A; Eldridge Gary R; Pasmore Mark E; Wood Thomas K
AN 2005348397 MEDLINE

L170 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2
TI Effect of treatment with 4,5-dihydroxy-2-cyclopenten-1-one (DHCP) on gene expression and **quorum-sensing** in bacteria
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
IN Phadtare, Sangita; Kato, Ikunoshin; Inouye, Masayori
AN 2003:757467 HCAPLUS
DN 139:271016

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2003077844	A2	20030925	WO 2003-US7081	20030307
	WO 2003077844	A3	20040325		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1482793 A2 20041208 EP 2003-713993 20030307
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005519616 T2 20050707 JP 2003-575898 20030307
 US 2006035317 A1 20060216 US 2005-506778 20050601

L170 ANSWER 3 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Growth-phase dependency of autoinducer-2 synthesis in *Helicobacter pylori*.
 SO Abstracts of the General Meeting of the American Society for Microbiology,
 (2003) Vol. 103, pp. D-083. [http://www.asmtgsrc/generalmeeting.ht](http://www.asmtgsrc/generalmeeting.htm)
 m. cd-rom.
 Meeting Info.: 103rd American Society for Microbiology General Meeting.
 Washington, DC, USA. May 18-22, 2003. American Society for Microbiology.
 ISSN: 1060-2011 (ISSN print).
 AU Terry, L. J. [Reprint Author]; Gumulak-Smith, J. J. [Reprint Author];
 Forsyth, M. H. [Reprint Author]
 AN 2003:519056 BIOSIS

L170 ANSWER 4 OF 5 MEDLINE on STN DUPLICATE 3
 TI The luxS gene is involved in cell-cell signalling for toxin production in
Clostridium perfringens.
 SO Molecular microbiology, (2002 Apr) Vol. 44, No. 1, pp. 171-9.
 Journal code: 8712028. ISSN: 0950-382X.
 AU Ohtani Kaori; Hayashi Hideo; Shimizu Tohru
 AN 2002230093 MEDLINE

L170 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Characterization of **quorum sensing** pathways in *E. coli*.
 SO Abstracts of the General Meeting of the American Society for Microbiology,
 (1999) Vol. 99, pp. 363. print.
 Meeting Info.: 99th General Meeting of the American Society for
 Microbiology. Chicago, Illinois, USA. May 30-June 3, 1999. American
 Society for Microbiology.
 ISSN: 1060-2011.
 AU Rather, P. N. [Reprint author]; Baca-Delancey, R. R. [Reprint author];
 Ding, X. [Reprint author]
 AN 1999:311307 BIOSIS

=> d ab 3-5

L170 ANSWER 3 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 AB Background: *Helicobacter pylori* is one of a diverse array of bacterial
 species with a density-dependent signal system. We previously
 demonstrated that *H. pylori* produces autoinducer-2 (AI-2) as a
quorum sensing molecule and that luxS is involved in its
 production. LuxS is the third gene in a putative three-gene operon (
cysK, metB, luxS). **cysK** and metB encode enzymes critical
 to amino acid synthesis. The mechanism of synthesis and detection of AI-2
 by *H. pylori* has not fully been elucidated, and the relationship between
 production of AI-2 and growth phase has received little attention. We
 hypothesize that **CysK**, MetB, and LuxS are part of the same
 metabolic pathway. Additionally, this study aims to examine the kinetics
 of AI-2 production in *H. pylori*. Methods: In order to characterize the
 production of AI-2 in *H. pylori* during other phases of growth, we isolated
 conditioned media (CM) from cultures of *H. pylori* J99 and 26695 at several

points during growth. The CM generated was assayed for AI-2 levels utilizing a *Vibrio harveyi* bioassay. We have generated a 26695 derivative, L26-3, that is a *luxS* merodiploid, containing an ectopic copy of *luxS* in *ureA*. We have also generated a *H. pylori* strain 26695 derivative (L26-4) with the genotype *cysK::CAT ure::luxS/ aphA3*. 26695, L26-3 and L26-4 were grown in broth to mid-log phase, and CM was generated. This CM was assayed for AI-2 using a *V. harveyi* bioassay. Results: While previous results have demonstrated that *H. pylori* strain 60190 has maximal AI-2 production in mid-log phase and that AI-2 production is greatly reduced in stationary phase cultures, we find that *H. pylori* strains 26695 and J99 putatively continue to produce AI-2 through stationary phase. Preliminary analysis of L26-3 revealed increased levels of AI-2 production. Analysis of L26-4 CM suggests that *cysK* may not be essential for AI-2 synthesis. Conclusions: The variation in AI-2 production through the phases of culture growth suggests that the production of AI-2 varies by *H. pylori* strain. Further analysis of the pathway leading to AI-2 production may serve to clarify the significance of this molecule in regulating gene expression in *H. pylori*.

L170 ANSWER 4 OF 5 MEDLINE on STN DUPLICATE 3
 AB A Gram-positive anaerobic pathogen, *Clostridium perfringens*, causes clostridial myonecrosis or gas gangrene in humans by producing numerous extracellular toxins and enzymes that act in concert to degrade host tissues. *C. perfringens* possesses a homologue of the *luxS* gene that is reported to be responsible for the production of autoinducer 2 (AI-2), which participates in **quorum sensing** in bacteria. The *luxS* mutant was constructed using *C. perfringens* strain 13, and the role of the *luxS* gene in toxin production was examined. The cell-free culture supernatant from wild-type strain 13 greatly stimulated the luminescence of *Vibrio harveyi* BB170, whereas that from the *luxS* mutant caused no significant stimulation, indicating that the *luxS* gene is necessary for AI-2 production in *C. perfringens*. The *luxS* mutant showed a reduced level of production of alpha-, kappa- and theta-toxins. In the *luxS* mutant, the transcription of the theta-toxin gene (*pfoA*) was lower at mid-exponential growth phase, whereas alpha- and kappa-toxin gene transcription was not significantly affected. The production of toxins in the *luxS* mutant was stimulated by the addition of the culture supernatant from the wild-type cells, possibly because of the presence of AI-2. Moreover, the expression of the *pfoA* gene in the *luxS* mutant was apparently activated when the mutant cells were cultured in the presence of culture supernatants from the wild-type *C. perfringens*, *Escherichia coli* DH5alpha carrying the *luxS* gene of *C. perfringens*. A deletion analysis of the *luxS* operon showed that the *luxS* gene alone is responsible for cell-cell signalling, and that the *metB* or *cysK* genes located upstream of *luxS* are not involved in regulating toxin production. Our results indicate that cell-cell signalling by AI-2 plays an important role in the regulation of toxin production in *C. perfringens*.

L170 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

=> s 1157 and 160

FILE 'MEDLINE'

L171 0 L146 AND L49

FILE 'SCISEARCH'

L172 0 L147 AND L50

FILE 'LIFESCI'

L173 0 L148 AND L51

FILE 'BIOTECHDS'

L174 0 L149 AND L52

FILE 'BIOSIS'

L175 0 L150 AND L53

FILE 'EMBASE'

L176 1 L151 AND L54

FILE 'HCAPLUS'

L177 0 L152 AND L55

FILE 'NTIS'

L178 0 L153 AND L56

FILE 'ESBIOBASE'

L179 0 L154 AND L57

FILE 'BIOTECHNO'

L180 0 L155 AND L58

FILE 'WPIDS'

L181 0 L156 AND L59

TOTAL FOR ALL FILES

L182 1 L157 AND L60

=> d

L182 ANSWER 1 OF 1 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

TI Acyl-homoserine lactone acylase from *Ralstonia* strain XJ12B represents a novel and potent class of quorum-quenching enzymes.

SO Molecular Microbiology, (2003) Vol. 47, No. 3, pp. 849-860. .

Refs: 58

ISSN: 0950-382X CODEN: MOMIEE

AU Lin Y.-H.; Xu J.-L.; Hu J.; Wang L.-H.; Leong Ong S.; Renton Leadbetter J.; Zhang L.-H.

AN 2003041693 EMBASE

=> d ab

L182 ANSWER 1 OF 1 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

AB N-acylhomoserine lactones (AHLs) are used as signal molecules by many **quorum-sensing** Proteobacteria. Diverse plant and animal pathogens use AHLs to regulate infection and virulence functions. These signals are subject to biological inactivation by AHL-lactonases and AHL-acylases. Previously, little was known about the molecular details underlying the latter mechanism. An AHL signal-inactivating bacterium, identified as a *Ralstonia* sp., was isolated from a mixed-species biofilm. The signal inactivation encoding gene from this organism, which we call *aiiD*, was cloned and successfully expressed in *Escherichia coli* and inactivated three AHLs tested. The predicted 794-amino-acid polypeptide was most similar to the aculeacin A acylase (AAC) from *Actinoplanes utahensis* and also shared significant similarities with cephalosporin acylases and other N-terminal (Ntn) hydrolases. However, the most similar homologues of *AiiD* are deduced proteins of undemonstrated function from available *Ralstonia*, *Deinococcus* and *Pseudomonas* genomes. LC-MS analyses demonstrated that *AiiD* hydrolyses the AHL amide, releasing homoserine lactone and the corresponding fatty acid. Expression of *AiiD* in *Pseudomonas aeruginosa* PAO1 quenched **quorum sensing** by this bacterium, decreasing its ability to swarm, produce elastase and pyocyanin and to paralyse nematodes. Thus, AHL-acylases have fundamental implications and hold biotechnological promise in quenching **quorum sensing**.

```

=> s 1157 and 184
FILE 'MEDLINE'
L183          8 L146 AND L73

FILE 'SCISEARCH'
L184          10 L147 AND L74

FILE 'LIFESCI'
L185          9 L148 AND L75

FILE 'BIOTECHDS'
L186          7 L149 AND L76

FILE 'BIOSIS'
L187          8 L150 AND L77

FILE 'EMBASE'
L188          9 L151 AND L78

FILE 'HCAPLUS'
L189          10 L152 AND L79

FILE 'NTIS'
L190          0 L153 AND L80

FILE 'ESBIOBASE'
L191          12 L154 AND L81

FILE 'BIOTECHNO'
L192          8 L155 AND L82

FILE 'WPIDS'
L193          1 L156 AND L83

TOTAL FOR ALL FILES
L194          82 L157 AND L84

=> s 1194 not 2004-2006/py
FILE 'MEDLINE'
      1332548 2004-2006/PY
              (20040000-20069999/PY)
L195          6 L183 NOT 2004-2006/PY

FILE 'SCISEARCH'
      2454856 2004-2006/PY
              (20040000-20069999/PY)
L196          6 L184 NOT 2004-2006/PY

FILE 'LIFESCI'
      189530 2004-2006/PY
L197          8 L185 NOT 2004-2006/PY

FILE 'BIOTECHDS'
      56959 2004-2006/PY
L198          4 L186 NOT 2004-2006/PY

FILE 'BIOSIS'
      1023506 2004-2006/PY
L199          6 L187 NOT 2004-2006/PY

FILE 'EMBASE'
      1117159 2004-2006/PY
L200          7 L188 NOT 2004-2006/PY

FILE 'HCAPLUS'

```

2548350 2004-2006/PY
L201 6 L189 NOT 2004-2006/PY

FILE 'NTIS'

25986 2004-2006/PY
L202 0 L190 NOT 2004-2006/PY

FILE 'ESBIOBASE'

664275 2004-2006/PY
L203 9 L191 NOT 2004-2006/PY

FILE 'BIOTECHNO'

586 2004-2006/PY
L204 8 L192 NOT 2004-2006/PY

FILE 'WPIDS'

2489972 2004-2006/PY
L205 0 L193 NOT 2004-2006/PY

TOTAL FOR ALL FILES

L206 60 L194 NOT 2004-2006/PY

=> dup rem l206

PROCESSING COMPLETED FOR L206

L207 14 DUP REM L206 (46 DUPLICATES REMOVED)

=> d tot

L207 ANSWER 1 OF 14 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Method of regulating genes in microorganisms, useful for e.g. increasing
production of recombinant proteins, comprises
treating gene-containing microorganism with 4,5-dihydroxy-2-cyclopenten-1-
one;
gene **expression** regulation and DNA array useful for
recombinant protein promotion
AU PHADTARE S; KATO I; INOUE M
AN 2003-25814 BIOTECHDS
PI WO 2003077844 25 Sep 2003

L207 ANSWER 2 OF 14 LIFESCI COPYRIGHT 2006 CSA on STN DUPLICATE 1
TI Characterization of RAP, a **quorum sensing** activator of
Staphylococcus aureus
SO FEMS Microbiology Letters [FEMS Microbiol. Lett.], (20030627) vol. 223,
no. 2, pp. 167-175.
ISSN: 0378-1097.
AU Korem, M.; Sheoran, A.S.; Gov, Y.; Tzipori, S.; Borovok, I.; Balaban, N.*
AN 2003:84905 LIFESCI

L207 ANSWER 3 OF 14 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
TI Crystal of LuxS protein which is involved in production of autoinducer-2
for identifying modulators useful for treating e.g. infection disease,
stomach cancer, stomach ulcer and other intestinal complications;
vector-mediated gene transfer, **expression** in host cell and
computer bioinformatic software for **recombinant**
protein production and drug screening
AU LEWIS H A
AN 2002-18835 BIOTECHDS
PI WO 2002038595 16 May 2002

L207 ANSWER 4 OF 14 MEDLINE on STN DUPLICATE 2
TI Genes encoding the N-acyl homoserine lactone-degrading enzyme are
widespread in many subspecies of Bacillus thuringiensis.
SO Applied and environmental microbiology, (2002 Aug) Vol. 68, No. 8, pp.
3919-24.
Journal code: 7605801. ISSN: 0099-2240.

AU Lee Sang Jun; Park Sun-Yang; Lee Jung-Ju; Yum Do-Young; Koo Bon-Tag; Lee Jung-Kee
AN 2002398079 MEDLINE

L207 ANSWER 5 OF 14 LIFESCI COPYRIGHT 2006 CSA on STN DUPLICATE 3
TI LuxS-dependent **quorum sensing** in *Porphyromonas gingivalis* modulates protease and haemagglutinin activities but is not essential for virulence
SO Microbiology, (20020300) vol. 148, no. 3, pp. 763-772.
ISSN: 1350-0872.
AU Burgess, N.A.; Kirke, D.F.; Williams, P.; Winzer, K.; Hardie, K.R.; Meyers, N.L.; Aduse-Opoku, J.; Curtis, M.A.; Camara, M.
AN 2002:77596 LIFESCI

L207 ANSWER 6 OF 14 MEDLINE on STN DUPLICATE 4
TI Effect of glycine on the cell yield and growth rate of *Escherichia coli*: evidence for cell-density-dependent glycine degradation as determined by ¹³C NMR spectroscopy.
SO Journal of biotechnology, (2002 Jan 18) Vol. 92, No. 3, pp. 237-49.
Journal code: 8411927. ISSN: 0168-1656.
AU Han Ling; Doverskog Magnus; Enfors Sven-Olof; Haggstrom Lena
AN 2001639835 MEDLINE

L207 ANSWER 7 OF 14 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
TI Bacterial autoinduction: Looking outside the cell for new metabolic engineering targets.
SO Microbial Cell Factories, (20 Dec 2002) Vol. 1, pp. 9p. .
Refs: 91
ISSN: 1475-2859 CODEN: MCFICT
AU DeLisa M.P.; Bentley W.E.
AN 2004253557 EMBASE

L207 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN
TI Bacterial autoinduction: looking outside the cell for new metabolic engineering targets
SO Microbial Cell Factories (2002), 1, No pp. given
CODEN: MCFICT; ISSN: 1475-2859
URL: <http://www.microbialcellfactories.com/content/pdf/1475-2859-1-5.pdf>
AU DeLisa, Matthew P.; Bentley, William E.
AN 2004:815256 HCAPLUS
DN 141:422094

L207 ANSWER 9 OF 14 MEDLINE on STN DUPLICATE 5
TI Mapping stress-induced changes in autoinducer AI-2 production in chemostat-cultivated *Escherichia coli* K-12.
SO Journal of bacteriology, (2001 May) Vol. 183, No. 9, pp. 2918-28.
Journal code: 2985120R. ISSN: 0021-9193.
AU DeLisa M P; Valdes J J; Bentley W E
AN 2001270821 MEDLINE

L207 ANSWER 10 OF 14 MEDLINE on STN DUPLICATE 6
TI Quorum signaling via AI-2 communicates the "Metabolic Burden" associated with **heterologous protein production** in *Escherichia coli*.
SO Biotechnology and bioengineering, (2001 Nov 20) Vol. 75, No. 4, pp. 439-50.
Journal code: 7502021. ISSN: 0006-3592.
AU DeLisa M P; Valdes J J; Bentley W E
AN 2001565037 MEDLINE

L207 ANSWER 11 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI Effect of glycine on the cell yield and growth rate of *Escherichia coli*: Evidence for cell-density-dependent glycine degradation as determined by

13C NMR spectroscopy.
SO Journal of Biotechnology, (18 January, 2001) Vol. 92, No. 3, pp. 237-249.
print.
CODEN: JBITD4. ISSN: 0168-1656.
AU Han, Ling; Doverskog, Magnus; Enfors, Sven-Olof; Haggstrom, Lena [Reprint
author]
AN 2002:147032 BIOSIS

L207 ANSWER 12 OF 14 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V.
on STN
AN 2001034881 ES BIOBASE
TI Co-overexpression of RspAB improves recombinant protein
production in Escherichia coli
AU Weikert C.; Canonaco F.; Sauer U.; Bailey J.E.
CS U. Sauer, Institute of Biotechnology, ETH Zurich, CH-8093 Zurich,
Switzerland.
E-mail: sauer@biotech.biol.ethz.ch
SO Metabolic Engineering, (2000), 2/4 (293-299), 34 reference(s)
CODEN: MEENFM ISSN: 1096-7176
DT Journal; Article
CY United States
LA English
SL English

L207 ANSWER 13 OF 14 MEDLINE on STN DUPLICATE 7
TI Characterization of the SarA virulence gene regulator of Staphylococcus
aureus.
SO Molecular microbiology, (1999 Jul) Vol. 33, No. 2, pp. 307-16.
Journal code: 8712028. ISSN: 0950-382X.
AU Rechlin T M; Gillaspay A F; Schumacher M A; Brennan R G; Smeltzer M S;
Hurlburt B K
AN 1999340210 MEDLINE

L207 ANSWER 14 OF 14 MEDLINE on STN DUPLICATE 8
TI Characterization of a novel RNA regulator of Erwinia carotovora ssp.
carotovora that controls production of extracellular enzymes and secondary
metabolites.
SO Molecular microbiology, (1998 Jul) Vol. 29, No. 1, pp. 219-34.
Journal code: 8712028. ISSN: 0950-382X.
AU Liu Y; Cui Y; Mukherjee A; Chatterjee A K
AN 1998367138 MEDLINE

=> d ab tot

L207 ANSWER 1 OF 14 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
AB DERWENT ABSTRACT:
NOVELTY - Method for regulating a gene (I) in a microorganism comprises
treating gene-containing microorganism with 4,5-dihydroxy-2-cyclopenten-1-
one (DHCP). (I) encodes a ribosomal protein or a protein of known or
unknown function or is involved in the response to stress, membrane
synthesis or function, or general metabolism.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1)
a method (M1) of screening for physiologically active compounds (A) by
determining the expression level of genes that are modulated by DHCP; (2)
(A) identified by (M1); (3) a method (M2) for increasing production of a
recombinant polypeptide in a microorganism by culturing it in presence of
DHCP; (4) a method (M3) for inhibiting an activity of an interspecies
quorum-sensing inducer, using DHCP; and (5) a
composition, containing DHCP, for: (a) regulating quorum
sensing; (b) regulating expression of specific genes;
(c) promoting secretion of recombinant proteins; or
(d) maintaining homeostasis.
ACTIVITY - None given.
MECHANISM OF ACTION - Gene Expression Regulator. Escherichia coli

JM83 was incubated in presence of 250 microM 4,5-dihydroxy-2-cyclopenten-1-one (DHCP), then RNA isolated and used to probe DNA arrays that represent all open-reading frames of E. coli K-12 W3110. Expression levels were compared with those in untreated cells. Most genes encoding ribosomal L proteins were downregulated (treated:control ratio 0.23-0.49); also (1) 40 genes encoding cell membrane-related proteins were affected, mostly downregulated but some, e.g. creD (unknown function) and tehA (tellurite resistance) were upregulated; (2) the rpoS gene, and genes regulated by the RpoS (a global stress-response regulator) protein were upregulated; (3) 44 genes involved in general metabolism were affected, particularly those implicated in Cys biosynthesis were upregulated and (4) 54 other genes, some of unknown function, were also modified, especially genes involved in resistance to tellurite and oxidative stress were upregulated. DHCP also eliminates the effect of the **quorum-sensing** inducer AI-2.

USE - The method uses DHCP as a regulator of a wide range of bacterial genes to: (1) manufacture a composition for regulating a gene in a microorganism; (2) inhibit activity of interspecies **quorum-sensing** inducers (**quorum-sensing** is associated with virulence, motility and outer membrane function); (3) promote secretion of recombinant proteins; and (4) maintain homeostasis (all claimed). (37 pages)

L207 ANSWER 2 OF 14 LIFESCI COPYRIGHT 2006 CSA on STN DUPLICATE 1

AB Staphylococcus aureus are Gram-positive bacteria and cause diverse serious diseases in humans and animals through the production of toxins. The production of toxins is regulated by **quorum sensing** mechanisms, where proteins such as RNAPIII activating protein (RAP) are secreted by the bacteria and induce virulence. Antibodies to RAP have been shown to protect mice from infection, but the molecular structure of RAP was not known and hindered vaccine development. To characterize RAP, recombinant protein was made and tested for its ability to induce genes important for pathogenesis (agr). In addition, monoclonal antibodies were produced to identify its cellular localization. Results shown here indicate that RAP is a 277-aa protein that is an ortholog of the ribosomal protein L2. Like the native molecule, **recombinant RAP** activates the **production** of RNAPIII (encoded by agr). Using RAP specific monoclonal antibodies we demonstrate that RAP is continuously secreted and while RAP is expressed also in other bacteria (like Staphylococcus epidermidis, Staphylococcus xylosus and Escherichia coli), it is secreted to the culture medium only by S. aureus. Our results show that the ribosomal protein L2 has an extraribosomal function and that when secreted RAP acts as an autoinducer of virulence to regulate S. aureus pathogenesis.

L207 ANSWER 3 OF 14 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

AB DERWENT ABSTRACT:

NOVELTY - A crystal (I) comprising LuxS protein (which is involved in the production of autoinducer-2 (AI-2), an intercellular signaling molecule employed in the **quorum sensing** pathway of various bacteria) or a functional LuxS protein subunit in crystalline form, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) a crystal (II) comprising a homolog of LuxS protein having a root mean square deviation of the alpha-carbon atoms of less than 2.0 Angstrom; (2) making (M1) (II) by mixing a volume of a solution comprising the LuxS protein with a volume of a reservoir solution comprising a precipitant and incubating the mixture obtained over the reservoir solution in a closed container, under conditions suitable for crystallization until the crystal forms; (3) determining (M2) the three-dimensional structure of a LuxS protein crystal, by providing (I) or (II) and analyzing the crystal by X-ray diffraction; (4) a machine-readable medium embedded with: (a) information that corresponds to a three-dimensional structural representation of (I) or (II); (b) molecular structure coordinates as shown in the specification or at least

50% of the coordinates; or (c) molecular structure coordinates of a protein molecule comprising LuxS protein binding pocket comprising at least three amino acids from Glu60, Arg68, Ile81 and Asp80, Ala64, His61, Tyr91, Ser9, Phe10 and Leu7, His14, Arg23, Asp40, Arg42, Met84, Cys86 and Thr88 having the structure coordinate as shown in the specification or by the structure coordinates of a binding pocket homolog where the root mean square deviation of the backbone atoms of the amino acid residues of the binding pocket and the binding pocket homolog is less than 2.0 Angstrom; (5) producing (M3) a mutant of LuxS protein having altered property related to LuxS protein by constructing a three-dimensional structure of LuxS protein having structure coordinates of (I)/(II); using modeling methods to identify in the three-dimensional structure at least one structural portion of the LuxS protein molecule, where an alteration in the structural portion is predicted to result in the altered property; providing a nucleic acid molecule having a modified sequence that encodes a deletion, insertion, or substitution of one or more amino acids at a position corresponding to the structural portion; and expressing the nucleic acid molecule to produce the mutant; (6) identifying (M4) a candidate binding compound capable of binding to the active site (or accessory binding site) of LuxS protein, by introducing into a computer program information derived from structural coordinates defining an active site (or accessory binding site) conformation of a LuxS protein molecule based upon three-dimensional structure determination comprising an active site (or accessory binding site) formed by at least the interaction of amino acids Glu, Arg, Ile and Asp where the program utilizes or displays their three-dimensional structure; generating a three-dimensional representation of the active site (or accessory binding site) cavity of the LuxS protein in the computer program; superimposing a model of the binding test compound on the model of the active site (or accessory binding site) of the LuxS protein; and assessing whether the test compound model fits spatially into the active site (or accessory binding site) of the LuxS protein; (7) selecting (M5) at least one compound that potentially binds to LuxS protein, by: (a) constructing a three-dimensional structure of LuxS protein and selecting at least one compound which potentially binds LuxS protein; (b) constructing a three-dimensional structure of a protein molecule comprising a LuxS protein binding pocket and computationally screening several compounds using the structure constructed; and (c) computationally screening a three-dimensional structural representation of a molecule comprising a LuxS protein binding pocket an identifying those that bind; (8) designing (M6) a compound that modulates LuxS protein activity by providing a computer modeling program with a set of structure coordinates, or a three-dimensional conformation derived from them, for a molecule that comprises a binding pocket having the structural coordinates of the binding pocket of LuxS protein, or a binding pocket homolog; computationally building a chemical entity represented by set of structure coordinates and determining whether the chemical entity is a modulator expected to bind to or interfere with the molecule; (9) a compound (C1) identified, designed or made by M4, M5 and M6; (10) a pharmaceutical composition comprising C1 or its salt and a carrier; (11) obtaining structural information about a molecule or a molecular complex of unknown structure by crystallizing the molecule or molecular complex; generating an x-ray diffraction pattern from the crystallized molecule or molecular complex and using a molecular replacement method to interpret the structure of the molecule, where the molecular replacement method uses the structure coordinates as given in the specification, or its subset, or the structure coordinates of the binding pocket; and (12) homology modeling a LuxS protein homolog by: (a) aligning the amino acid sequence of LuxS protein homolog with an amino acid sequence of LuxS protein; (b) incorporating the sequence of homolog into a model of the structure of LuxS protein; (c) subjecting the preliminary model to energy minimization to yield an energy minimized model; and (d) remodeling regions of the energy minimized model where stereochemistry restraint are violated to yield a final model of the homolog.

BIOTECHNOLOGY - Preferred Crystal: (I) is preferably diffraction

quality, is an apo-crystal, a native crystal, and/or is a heavy-atom derivative crystal, where LuxS is *Helicobacter pylori*, *Haemophilus influenzae* or *Deinococcus radiodurans* LuxS, or a mutant which is selenomethionine, selenocysteine mutant, conservative mutant, truncated or extended mutant. (I) is characterized by a set of structure coordinate that is substantially similar to the set of structure coordinates as given in the specification. (II) is produced by mixing a volume of a solution comprising the LuxS protein with a volume of a reservoir solution comprising a precipitant and incubating the mixture obtained over the reservoir solution in a closed container, under conditions suitable for crystallization until the crystal forms. Protein co-ordinate data is given in the patent specification. Preferred Method: In M3, the altered activity of LuxS protein is preferably altered binding activity or immunogenicity, where an epitope is altered. In M4, the structural coordinates correspond to the liganded or unliganded LuxS protein, and the binding compound is a LuxS inhibitor. M5 further comprises screening a library of compounds. The binding pocket comprises at least three amino acids from Glu60, Arg68, Ile81 and Asp80, Ala64, His61, Tyr91, Ser9, Phe10 and Leu7, His14, Arg23, Asp40, Arg42, Met84, Cys86 and Thr88 having the structure coordinate as shown in the specification or a molecule comprising a binding pocket homolog where the root mean square deviation of the backbone atoms of the amino acid residues of the binding pocket and the binding pocket homolog is less than 2.0 Angstrom. The method comprises determining whether the compound potentially binds to the molecule by performing a fitting operation between the compound and a binding pocket of the molecule or molecular complex, and computationally analyzing the results of the fitting operation to quantify the association between, or the interference with, the compound and the binding pocket.

ACTIVITY - Antibacterial; Cytostatic; Antiulcer. No supporting biological data is given.

MECHANISM OF ACTION - LuxS protein modulator (claimed). No supporting biological data is given.

USE - C1 is useful for modulating LuxS protein activity (claimed), useful for treating e.g. infection disease, stomach cancer, stomach ulcer and other intestinal complications.

ADMINISTRATION - C1 is administered through oral, buccal, sublingual, rectal, transdermal, vaginal, transmucosal, nasal or intestinal administration, parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal or intraocular injections. Dosage of C1 is for 0.01-1000 (preferably 10-30) mg/day.

EXAMPLE - An open-reading frame for LuxS was amplified from *Helicobacter pylori* (Hp-ATCC43504D) genomic DNA by the polymerase chain reaction (PCR) using the following primers: Forward primer GGATTTTCACATATGAAAATGAATGTAGAGAGTTTC, Reverse Primer: GTTCGGATCCAACCCCACTTCAGACC. The PCR product (456 bp expected) was digested with NdeI and BamHI, electrophoresed on a 1% agarose gel in TBE buffer and the appropriate size band was excised from the gel and eluted using a standard gel extraction kit. The eluted DNA was ligated overnight with T4 DNA ligase at 16 degreesC into pSB3, previously digested with NdeI and BamHI. The vector pSB3 was a modified version of pET26b where the following sequence had been inserted into the BamHI site: GGATCCCACCACCACCACCACCTGAGATCC. The resulting sequence of the gene after being ligated into the vector, from the Shine-Dalgarno sequence through the stop site and the original BamHI, site was as follows: AAGGAGGAGATATACATATG(open reading frame (ORF))GGATCCCACCACCACCACCACCTGAGATCC. The LuxS expressed using this vector had 8 amino acids to the C-terminal end (Gly-Ser-His-His-His-His-His-His). Plasmids containing ligated inserts were transformed into chemically competent *Escherichia coli* such as Top 10 cells. Colonies were then screened for inserts in the correct orientation and miniprep. The miniprep DNA was transformed into BL21 (DE3) Active Motif cells and plated onto petri dishes containing Luria-Bertani medium (LB) agar with 30 mug/ml of kanamycin. Isolated, single colonies were grown to mid-log phase and stored at -80

degrees Centigrade in LB containing 15% glycerol. LuxS containing selenomethionine was overexpressed in *Escherichia coli* and the cultures were allowed to ferment overnight and the LuxS was purified. For crystals of *Helicobacter pylori* from which the molecular structure coordinates of were obtained, it had been found that a hanging drop containing 1 microlitre of LuxS polypeptide 5 mg/mL in 10 mM HEPES pH 7.5, 150 mM NaCl, 1 mM betaME, 10 mM methionine, and 1 microlitre reservoir solution 32% (w/v) PEG1000, 200 mM ammonium sulfate, 2 mM beta-mercaptoethanol, and 100 mM MES, pH 5.75 in a sealed container containing 500 microlitres reservoir solution, incubated for 3-7 days at 20 degrees Centigrade provide diffraction quality crystals.(473 pages)

L207 ANSWER 4 OF 14 MEDLINE on STN

DUPLICATE 2

AB Gram-negative bacteria can communicate with each other by N-acyl homoserine lactones (AHLs), which are **quorum-sensing** autoinducers. Recently, the *aiiA* gene (encoding an enzyme catalyzing the degradation of AHL) has been cloned from *Bacillus* sp. strain 240B1. During investigations in the course of the ongoing *Bacillus thuringiensis* subsp. *morrisoni* genome project, an *aiiA* homologue gene in the genome sequence was found. These results led to consideration of the possibility of the widespread existence of the gene in *B. thuringiensis*. *aiiA* homologue genes were found in 16 subspecies of *B. thuringiensis*, and their sequences were determined. Comparison of the *Bacillus* sp. strain 240B1 *aiiA* gene with the *B. thuringiensis* *aiiA* homologue genes showed high homologies of 89 to 95% and 90 to 96% in the nucleotide sequence and deduced amino acid sequence, respectively. Among the subspecies of *B. thuringiensis* having an *aiiA* gene, the subspecies *aizawai*, *galleriae*, *kurstaki*, *kyushuensis*, *ostriniae*, and *subtoxicius* were shown to degrade AHL. It was observed that **recombinant** *Escherichia coli* **producing AiiA proteins** also had AHL-degrading activity and could also attenuate the plant pathogenicity of *Erwinia carotovora*. These results indicate that insecticidal *B. thuringiensis* strains might have potential to compete with gram-negative bacteria in natural ecosystems by autoinducer-degrading activity.

L207 ANSWER 5 OF 14 LIFESCI COPYRIGHT 2006 CSA on STN DUPLICATE 3

AB *Porphyromonas gingivalis* is a Gram-negative black-pigmented obligate anaerobe implicated in the aetiology of human periodontal disease. The virulence of *P. gingivalis* is associated with the elaboration of the cysteine proteases Arg-gingipain (Rgp) and Lys-gingipain (Kgp), which are produced at high bacterial cell densities. To determine whether **quorum sensing** plays a role in the regulation of Rgp and Kgp, biosensors capable of detecting either N-acylhomoserine lactone (AHLs) or the luxS-dependent autoinducer (AI-2) **quorum-sensing** signalling molecules in spent culture supernatants were first employed. While no AHLs could be detected, the *Vibrio harveyi* BB170 biosensor was activated by spent *P. gingivalis* W50 culture supernatants. The *P. gingivalis* luxS gene was cloned and demonstrated to restore AI-2 production in the *Escherichia coli* luxS mutant DH5 alpha. Mutation of luxS abolished AI-2 **production** in *P. gingivalis*. Western blotting using antibodies raised against the **recombinant protein** revealed that LuxS levels increased throughout growth even though AI-2 activity was only maximally detected at the mid-exponential phase of growth and disappeared by the onset of stationary phase. Similar results were obtained with *E. coli* DH5 alpha transformed with luxS, suggesting that AI-2 production is not limited by a lack of LuxS protein. Analysis of Rgp and Kgp protease activities revealed that the *P. gingivalis* luxS mutant produced around 45% less Rgp and 30% less Kgp activity than the parent strain. In addition, the luxS mutant exhibited a fourfold reduction in haemagglutinin titre. However, these reductions in virulence determinant levels were insufficient to attenuate the luxS mutant in a murine lesion model of *P. gingivalis* infection.

L207 ANSWER 6 OF 14 MEDLINE on STN

DUPLICATE 4

AB Addition of selected amino acids could be a means to improve

production of recombinant proteins in industrial processes. We found that glycine increased the maximum specific growth rate of *Escherichia coli* from 0.67 to 0.78 h⁻¹, and the cell yield from 0.57 to 0.98 g dry weight per g substrate, when supplemented to batch cultures in a glucose-mineral medium. Maximum effect occurred at pH 6.8, at a glycine concentration of 6-12 mmol l⁻¹, and at cell densities below 1.15 g dry weight l⁻¹ (OD₆₁₀ 0.3). When glycine was added to a culture at a cell density of 1.15 g l⁻¹ or above, no growth promoting effect of glycine was seen. The 'glycine effect' was not due to CO₂ produced by the glycine cleavage system (GCV), and the lack of effect at higher cell densities was not masked by acetate accumulation, but coincided with increased acetate production. The metabolism of glycine was further investigated in cultures supplied with [2-(¹³C)] labelled glycine, and the redistribution of label in the [1-(¹³C)], [2-(¹³C)], and [1,2-(¹³C)] isotopomers of excreted acetate was analysed by ¹³C NMR. The NMR data revealed that very little degradation of glycine occurred at cell densities below 1.15 g l⁻¹. Simultaneously the biosynthesis of serine and glycine was repressed as judged by the absence of [2-(¹³C)] acetate, implying that added glycine was used as a source of glycine, serine, one-carbon units, and threonine. At cell densities above 1.15 g l⁻¹, 53% of the consumed glycine carbon was excreted as acetate. Degradation of glycine was associated with an increased uptake rate, cleavage by GCV, and degradation of both glycine-derived serine, and glucose-derived serine to pyruvate. This switch in metabolism appears to be regulated by **quorum sensing**.

L207 ANSWER 7 OF 14 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

AB Recent evidence has demonstrated that cell-to-cell signaling is a fundamental activity carried out by numerous microorganisms. A number of specialized processes are reported to be regulated by density-dependent signaling molecules including antibiotic production, bioluminescence, biofilm formation, genetic competence, sporulation, swarming motility and virulence. However, a more centralized role for **quorum sensing** is emerging where quorum signaling pathways overlap with stress and starvation circuits to regulate cellular adaptation to changing environmental conditions. The interplay of these phenomena is especially critical in the **expression of recombinant proteins** where elicitation of stress responses can dramatically impact cellular **productivity**. .COPYRG. 2002 DeLisa and Bentley; licensee BioMed Central Ltd.

L207 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN

AB A review. Recent evidence has demonstrated that cell-to-cell signaling is a fundamental activity carried out by numerous microorganisms. A number of specialized processes are reported to be regulated by d.-dependent signaling mols. including antibiotic production, bioluminescence, biofilm formation, genetic competence, sporulation, swarming motility and virulence. However, a more centralized role for **quorum sensing** is emerging where quorum signaling pathways overlap with stress and starvation circuits to regulate cellular adaptation to changing environmental conditions. The interplay of these phenomena is especially critical in the **expression of recombinant proteins** where elicitation of stress responses can dramatically impact cellular **productivity**.

L207 ANSWER 9 OF 14 MEDLINE on STN DUPLICATE 5

AB Numerous gram-negative bacteria employ a cell-to-cell signaling mechanism, termed **quorum sensing**, for controlling gene expression in response to population density. Recently, this phenomenon has been discovered in *Escherichia coli*, and while pathogenic *E. coli* utilize **quorum sensing** to regulate pathogenesis (i.e., expression of virulence genes), the role of **quorum**

sensing in nonpathogenic *E. coli* is less clear, and in particular, there is no information regarding the role of **quorum sensing** during the overexpression of recombinant proteins. The production of autoinducer AI-2, a signaling molecule employed by *E. coli* for intercellular communication, was studied in *E. coli* W3110 chemostat cultures using a *Vibrio harveyi* AI-2 reporter assay (M. G. Surette and B. L. Bassler, Proc. Natl. Acad. Sci. USA 95:7046-7050, 1998). Chemostat cultures enabled a study of AI-2 regulation through steady-state and transient responses to a variety of environmental stimuli. Results demonstrated that AI-2 levels increased with the steady-state culture growth rate. In addition, AI-2 increased following pulsed addition of glucose, Fe(III), NaCl, and dithiothreitol and decreased following aerobiosis, amino acid starvation, and isopropyl-beta-D-thiogalactopyranoside-induced expression of human interleukin-2 (hIL-2). In general, the AI-2 responses to several perturbations were indicative of a shift in metabolic activity or state of the cells induced by the individual stress. Because of our interest in the **expression of heterologous proteins** in *E. coli*, the transcription of four quorum-regulated genes and 20 stress genes was mapped during the transient response to induced expression of hIL-2. Significant regulatory overlap was revealed among several stress and starvation genes and known **quorum-sensing** genes.

L207 ANSWER 10 OF 14 MEDLINE on STN DUPLICATE 6
 AB Recent reports have shown that bacterial cell-cell communication or **quorum sensing** is quite prevalent in pathogenic *Escherichia coli*, especially at high cell density; however, the role of **quorum sensing** in nonpathogenic *E. coli* is less clear and, in particular, there is no information regarding the role of **quorum sensing** in overexpression of plasmid-encoded genes. In this work, it was found that the activity of a quorum signaling molecule, autoinducer-2 (AI-2), decreased significantly following induction of several plasmid-encoded genes in both low and high-cell-density cultures of *E. coli*. Furthermore, we show that AI-2 signaling level was linearly related to the accumulation level of each protein **product** and that, in general, the highest rates of **recombinant protein** accumulation resulted in the greatest attenuation of AI-2 signaling. Importantly, our findings demonstrate for the first time that recombinant *E. coli* communicate the stress or burden of overexpressing heterologous genes through the quorum-based AI-2 signaling pathway.
 Copyright 2001 John Wiley & Sons, Inc.

L207 ANSWER 11 OF 14 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 AB Addition of selected amino acids could be a means to improve **production of recombinant proteins** in industrial processes. We found that glycine increased the maximum specific growth rate of *Escherichia coli* from 0.67 to 0.78 h⁻¹, and the cell yield from 0.57 to 0.98 g dry weight per g substrate, when supplemented to batch cultures in a glucose-mineral medium. Maximum effect occurred at pH 6.8, at a glycine concentration of 6-12 mmol l⁻¹, and at cell densities below 1.15 g dry weight l⁻¹ (OD610cntdot3). When glycine was added to a culture at a cell density of 1.15 g l⁻¹ or above, no growth promoting effect of glycine was seen. The 'glycine effect' was not due to CO₂ produced by the glycine cleavage system (GCV), and the lack of effect at higher cell densities was not masked by acetate accumulation, but coincided with increased acetate production. The metabolism of glycine was further investigated in cultures supplied with (2-¹³C) labelled glycine, and the redistribution of label in the (1-¹³C), (2-¹³C), and (1,2-¹³C) isotopomers of excreted acetate was analysed by ¹³C NMR. The NMR data revealed that very little degradation of glycine occurred at cell densities below 1.15 g l⁻¹. Simultaneously the biosynthesis of serine and glycine was repressed as judged by the absence of (2-¹³C) acetate, implying that added glycine was used as a source of glycine,

serine, one-carbon units, and threonine. At cell densities above 1.15 g 1-1, 53% of the consumed glycine carbon was excreted as acetate. Degradation of glycine was associated with an increased uptake rate, cleavage by GCV, and degradation of both glycine-derived serine, and glucose-derived serine to pyruvate. This switch in metabolism appears to be regulated by **quorum sensing**.

L207 ANSWER 12 OF 14 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN

AB The *Escherichia coli* mutant CWML2 was previously reported to exhibit improved physiological characteristics, including **recombinant protein production**. Here we investigate the molecular basis of this phenotype by comparing the cellular level of three RNA polymerase sigma subunits by immunoblot analysis. While the level of housekeeping σ .sup.D was similar in parent and mutant, the levels of the flagella synthesis regulator σ .sup.F and the stationary phase regulator σ .sup.S were higher in the mutant strain, indicating a different motility and stationary phase phenotype. Evidence for this conclusion was provided by the significantly higher motility of CWML2, compared to its parent. Based on these results, we hypothesized that alterations in ppGpp regulation via a homoserine lactone-dependent mechanism may be relevant for the mutant phenotype. Indeed, transcription of the *rspAB* operon, which was previously described to be involved in the degradation of homoserine lactone, was found to be deregulated in CWML2 in a plasmid-based reporter protein assay. By overexpression of the *E. coli* *rspAB* operon, we could partly mimic the mutant phenotype and demonstrate that co-overexpression of *RspAB* is a pertinent metabolic engineering strategy to improve **recombinant protein production**. .COPYRGT. 2000 Academic Press.

L207 ANSWER 13 OF 14 MEDLINE on STN DUPLICATE 7

AB *Staphylococcus aureus* is a potent human pathogen that expresses a large number of virulence factors in a temporally regulated fashion. Two pleiotropically acting regulatory loci were identified in previous mutational studies. The *agr* locus comprises two operons that express a **quorum-sensing** system from the P2 promoter and a regulatory RNA molecule from the P3 promoter. The *sar* locus encodes a DNA-binding protein that activates the expression of both *agr* operons. We have cloned the *sarA* gene, **expressed** *SarA* in *Escherichia coli* and purified the **recombinant protein** to apparent homogeneity. The purified protein was found to be dimeric in the presence and absence of DNA and to consist mostly of alpha-helices. DNase I footprinting of *SarA* on the putative regulatory region cis to the *agr* promoters revealed three high-affinity binding sites composed of two half-sites each. Quantitative electrophoretic mobility shift assays (EMSAs) were used to derive equilibrium binding constants (KD) for the interaction of *SarA* with these binding sites. An unusual ladder banding pattern was observed in EMSA with a large DNA fragment including all three binding sites. Our data indicate that *SarA* regulation of the *agr* operons involves binding to multiple half-sites and may involve other sites located downstream of the promoters.

L207 ANSWER 14 OF 14 MEDLINE on STN DUPLICATE 8

AB The enterobacterium *Erwinia carotovora* ssp. *carotovora* strain 71 (hereafter Ecc71) produces extracellular enzymes such as pectate lyase isozymes (Pels), cellulase (Cel), polygalacturonase (Peh) and protease (Prt). These enzymes degrade plant cell wall components and are largely responsible for the elicitation of soft-rot diseases in plants and plant products. Ecc71 also produces HarpinEcc, the elicitor of hypersensitive reaction (HR) and the **quorum-sensing** signal, N-(3-oxohexanoyl)-L-homoserine lactone (OHL). OHL controls extracellular enzyme and HarpinEcc production. The levels of these enzymes, as well as the expression of *hrpNEcc*, the structural gene for HarpinEcc, and *ohll*, the gene specifying OHL synthesis, are negatively regulated by *RsmA*. *rsmB*, formerly *aepH*, on the other hand, positively regulates extracellular

enzyme production. 6His-RsmA recombinant protein purified from E. coli binds rsmB RNA as indicated by gel mobility shift assays. rsmB comprises 547 bp DNA, which is transcribed from a single start site immediately after a sigma70-like promoter. In Ecc71, two rsmB RNA species are detected: a full-length 479 base rsmB RNA and a 259 base rsmB' RNA. rsmB' DNA hybridizes with the 259 base and the 479 base transcripts. A 3' RNase protection assay revealed that the 259 base and the 479 base RNA species end at the same position immediately after the putative rho-independent terminator. The expression of rsmB-lacZ transcriptional fusions established that the rsmB' RNA is not produced because of the activation of an internal promoter. These data strongly suggest that the 259 base rsmB' RNA is derived by processing of the primary rsmB RNA. In Ecc71, rsmB' expression driven by the lac promoter causes overproduction of Pel, Peh, Cel and Prt, and accumulation of pel-1, peh-1, hrpNEcc and ohl1 transcripts. By contrast, a plasmid with the rsmB' DNA sequence deleted fails to cause overproduction of the extracellular enzymes in Ecc71. The rsmB' effect also occurs in Escherichia coli as glycogen accumulation is stimulated in the presence of rsmB'. In vivo and in vitro translation as well as mutational analysis of rsmB' have established that rsmB' RNA does not yield a translational product. Therefore, we concluded that the rsmB' RNA itself functions as the regulator. Indeed, the expression rsmB' DNA leads to neutralization of the negative effects of the RNA-binding protein, RsmA, in Ecc71 and Serratia marcescens strain SM274. We propose a model that explains how RsmA and rsmB control the expression of genes for extracellular enzymes.

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	504.85	505.06
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.75	-6.75

STN INTERNATIONAL LOGOFF AT 17:51:33 ON 10 MAR 2006